CN114599636A - B型肝炎抗病毒剂 - Google Patents
B型肝炎抗病毒剂 Download PDFInfo
- Publication number
- CN114599636A CN114599636A CN202080055673.0A CN202080055673A CN114599636A CN 114599636 A CN114599636 A CN 114599636A CN 202080055673 A CN202080055673 A CN 202080055673A CN 114599636 A CN114599636 A CN 114599636A
- Authority
- CN
- China
- Prior art keywords
- radical
- halogen
- alkyl
- compound
- carbocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000002672 hepatitis B Diseases 0.000 title abstract description 10
- 239000003443 antiviral agent Substances 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 132
- 150000003839 salts Chemical class 0.000 claims abstract description 29
- 239000000651 prodrug Substances 0.000 claims abstract description 28
- 229940002612 prodrug Drugs 0.000 claims abstract description 28
- 239000012453 solvate Substances 0.000 claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 23
- 150000003254 radicals Chemical class 0.000 claims description 163
- 229910052736 halogen Inorganic materials 0.000 claims description 98
- 150000002367 halogens Chemical class 0.000 claims description 98
- -1 C2-6Alkenyl radical Chemical class 0.000 claims description 88
- 125000003118 aryl group Chemical group 0.000 claims description 58
- 229910052739 hydrogen Inorganic materials 0.000 claims description 57
- 239000001257 hydrogen Substances 0.000 claims description 57
- 150000002431 hydrogen Chemical class 0.000 claims description 48
- 125000000217 alkyl group Chemical group 0.000 claims description 32
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 31
- 125000000623 heterocyclic group Chemical group 0.000 claims description 27
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 24
- 229910052799 carbon Inorganic materials 0.000 claims description 20
- 229910052757 nitrogen Inorganic materials 0.000 claims description 20
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 14
- 239000011737 fluorine Substances 0.000 claims description 13
- 125000004429 atom Chemical group 0.000 claims description 12
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 11
- 229910052805 deuterium Inorganic materials 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 9
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 6
- 125000002837 carbocyclic group Chemical group 0.000 claims description 5
- 125000006706 (C3-C6) carbocyclyl group Chemical group 0.000 claims description 3
- 150000005840 aryl radicals Chemical class 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 15
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 200
- 238000005160 1H NMR spectroscopy Methods 0.000 description 100
- 239000000203 mixture Substances 0.000 description 30
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 23
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- 235000002639 sodium chloride Nutrition 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 239000002552 dosage form Substances 0.000 description 16
- 241000700721 Hepatitis B virus Species 0.000 description 15
- 239000000546 pharmaceutical excipient Substances 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 210000000234 capsid Anatomy 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 125000001072 heteroaryl group Chemical group 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 8
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 description 8
- 239000000460 chlorine Substances 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 235000019439 ethyl acetate Nutrition 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 7
- 108091036055 CccDNA Proteins 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 7
- 229910052794 bromium Inorganic materials 0.000 description 7
- 229910052801 chlorine Inorganic materials 0.000 description 7
- 229910052731 fluorine Inorganic materials 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 6
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 229940032147 starch Drugs 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- 235000010356 sorbitol Nutrition 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 101710132601 Capsid protein Proteins 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000008156 Ringer's lactate solution Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- 239000008135 aqueous vehicle Substances 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 229940124765 capsid inhibitor Drugs 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 235000012343 cottonseed oil Nutrition 0.000 description 3
- 239000002385 cottonseed oil Substances 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 239000002687 nonaqueous vehicle Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 235000010487 tragacanth Nutrition 0.000 description 3
- 229940116362 tragacanth Drugs 0.000 description 3
- 239000008136 water-miscible vehicle Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- LXJOYRVJPWDJBZ-UHFFFAOYSA-N (2-acetamido-3-hydroxyphenyl)arsonic acid Chemical compound OC=1C(=C(C=CC1)[As](O)(O)=O)NC(C)=O LXJOYRVJPWDJBZ-UHFFFAOYSA-N 0.000 description 2
- AXNUZKSSQHTNPZ-UHFFFAOYSA-N 3,4-difluoroaniline Chemical compound NC1=CC=C(F)C(F)=C1 AXNUZKSSQHTNPZ-UHFFFAOYSA-N 0.000 description 2
- IWQRJKGYECVOAA-UHFFFAOYSA-N 3-hexoxycarbonylbenzoic acid Chemical compound CCCCCCOC(=O)C1=CC=CC(C(O)=O)=C1 IWQRJKGYECVOAA-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical class NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- QWQONZVLXJGXHV-UHFFFAOYSA-N [chlorosulfonyloxy(dimethyl)silyl]methane Chemical compound C[Si](C)(C)OS(Cl)(=O)=O QWQONZVLXJGXHV-UHFFFAOYSA-N 0.000 description 2
- 229960004748 abacavir Drugs 0.000 description 2
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229960001997 adefovir Drugs 0.000 description 2
- 229960003205 adefovir dipivoxil Drugs 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 229940090805 clavulanate Drugs 0.000 description 2
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000008139 complexing agent Substances 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000002577 cryoprotective agent Substances 0.000 description 2
- PFWWSGFPICCWGU-UHFFFAOYSA-N cyclopropanesulfonyl chloride Chemical compound ClS(=O)(=O)C1CC1 PFWWSGFPICCWGU-UHFFFAOYSA-N 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 229960000366 emtricitabine Drugs 0.000 description 2
- 229960000980 entecavir Drugs 0.000 description 2
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 description 2
- XKAWEJUJIOUTRS-UHFFFAOYSA-N ethyl 3-fluoro-1h-pyrrole-2-carboxylate Chemical compound CCOC(=O)C=1NC=CC=1F XKAWEJUJIOUTRS-UHFFFAOYSA-N 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 229960004396 famciclovir Drugs 0.000 description 2
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 229960002963 ganciclovir Drugs 0.000 description 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229940097042 glucuronate Drugs 0.000 description 2
- 239000003979 granulating agent Substances 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 229960001627 lamivudine Drugs 0.000 description 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 229960005015 local anesthetics Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- GVWISOJSERXQBM-UHFFFAOYSA-N n-methylpropan-1-amine Chemical compound CCCNC GVWISOJSERXQBM-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 229960001179 penciclovir Drugs 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229960000540 polacrilin potassium Drugs 0.000 description 2
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000008137 solubility enhancer Substances 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 229960005311 telbivudine Drugs 0.000 description 2
- IQFYYKKMVGJFEH-CSMHCCOUSA-N telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 description 2
- 229960004556 tenofovir Drugs 0.000 description 2
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Substances ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- STPKWKPURVSAJF-LJEWAXOPSA-N (4r,5r)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-4-ol Chemical compound O[C@H]1C(CCCC)(CCCC)CS(=O)(=O)C2=CC=C(N(C)C)C=C2[C@H]1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C[N+]1(CC2)CCN2CC1 STPKWKPURVSAJF-LJEWAXOPSA-N 0.000 description 1
- VUEGYUOUAAVYAS-JGGQBBKZSA-N (6ar,9s,10ar)-9-(dimethylsulfamoylamino)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NS(=O)(=O)N(C)C)=C3C2=CNC3=C1 VUEGYUOUAAVYAS-JGGQBBKZSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- DQXKOHDUMJLXKH-PHEQNACWSA-N (e)-n-[2-[2-[[(e)-oct-2-enoyl]amino]ethyldisulfanyl]ethyl]oct-2-enamide Chemical compound CCCCC\C=C\C(=O)NCCSSCCNC(=O)\C=C\CCCCC DQXKOHDUMJLXKH-PHEQNACWSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 1
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- QXOGPTXQGKQSJT-UHFFFAOYSA-N 1-amino-4-[4-(3,4-dimethylphenyl)sulfanylanilino]-9,10-dioxoanthracene-2-sulfonic acid Chemical compound Cc1ccc(Sc2ccc(Nc3cc(c(N)c4C(=O)c5ccccc5C(=O)c34)S(O)(=O)=O)cc2)cc1C QXOGPTXQGKQSJT-UHFFFAOYSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- AAQTWLBJPNLKHT-UHFFFAOYSA-N 1H-perimidine Chemical compound N1C=NC2=CC=CC3=CC=CC1=C32 AAQTWLBJPNLKHT-UHFFFAOYSA-N 0.000 description 1
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 1
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 1
- VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 description 1
- QEBYEVQKHRUYPE-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-[(1-methylpyrazol-3-yl)methyl]-4-[[methyl(pyridin-3-ylmethyl)amino]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CN(C)N=C1CN1C(=O)C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C1CN(C)CC1=CC=CN=C1 QEBYEVQKHRUYPE-UHFFFAOYSA-N 0.000 description 1
- WGIMXKDCVCTHGW-UHFFFAOYSA-N 2-(2-hydroxyethoxy)ethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOCCO WGIMXKDCVCTHGW-UHFFFAOYSA-N 0.000 description 1
- KKFDCBRMNNSAAW-UHFFFAOYSA-N 2-(morpholin-4-yl)ethanol Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 description 1
- OXQGTIUCKGYOAA-UHFFFAOYSA-N 2-Ethylbutanoic acid Chemical compound CCC(CC)C(O)=O OXQGTIUCKGYOAA-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- ASNHGEVAWNWCRQ-UHFFFAOYSA-N 4-(hydroxymethyl)oxolane-2,3,4-triol Chemical compound OCC1(O)COC(O)C1O ASNHGEVAWNWCRQ-UHFFFAOYSA-N 0.000 description 1
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
- MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- HSBKFSPNDWWPSL-VDTYLAMSSA-N 4-amino-5-fluoro-1-[(2s,5r)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one Chemical compound C1=C(F)C(N)=NC(=O)N1[C@@H]1C=C[C@H](CO)O1 HSBKFSPNDWWPSL-VDTYLAMSSA-N 0.000 description 1
- DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 description 1
- VKLKXFOZNHEBSW-UHFFFAOYSA-N 5-[[3-[(4-morpholin-4-ylbenzoyl)amino]phenyl]methoxy]pyridine-3-carboxamide Chemical compound O1CCN(CC1)C1=CC=C(C(=O)NC=2C=C(COC=3C=NC=C(C(=O)N)C=3)C=CC=2)C=C1 VKLKXFOZNHEBSW-UHFFFAOYSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- HCCNBKFJYUWLEX-UHFFFAOYSA-N 7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)-3-(pyrazin-2-ylmethylamino)pyrido[3,4-b]pyrazin-2-one Chemical compound O=C1N(CCOCCC)C2=CC(C=3C=NC(OC)=CC=3)=NC=C2N=C1NCC1=CN=CC=N1 HCCNBKFJYUWLEX-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- XASOHFCUIQARJT-UHFFFAOYSA-N 8-methoxy-6-[7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one Chemical compound C(N1C(=O)C2=C(OC)C=C(C=3N4C(=NC=3)C=C(C=C4)OCCN3CCOCC3)C=C2CC1)C(F)(F)F XASOHFCUIQARJT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 description 1
- 101710127675 Antiviral innate immune response receptor RIG-I Proteins 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- PKWRMUKBEYJEIX-DXXQBUJASA-N Birinapant Chemical compound CN[C@@H](C)C(=O)N[C@@H](CC)C(=O)N1C[C@@H](O)C[C@H]1CC1=C(C2=C(C3=CC=C(F)C=C3N2)C[C@H]2N(C[C@@H](O)C2)C(=O)[C@H](CC)NC(=O)[C@H](C)NC)NC2=CC(F)=CC=C12 PKWRMUKBEYJEIX-DXXQBUJASA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 1
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 101150103227 IFN gene Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000218652 Larix Species 0.000 description 1
- 235000005590 Larix decidua Nutrition 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- AVYVHIKSFXVDBG-UHFFFAOYSA-N N-benzyl-N-hydroxy-2,2-dimethylbutanamide Chemical compound C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O AVYVHIKSFXVDBG-UHFFFAOYSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 244000134552 Plantago ovata Species 0.000 description 1
- 235000003421 Plantago ovata Nutrition 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000009223 Psyllium Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 229910006124 SOCl2 Inorganic materials 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229940124615 TLR 7 agonist Drugs 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- RLAHNGKRJJEIJL-RFZPGFLSSA-N [(2r,4r)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@H]1CO[C@@H](CO)O1 RLAHNGKRJJEIJL-RFZPGFLSSA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229950005846 amdoxovir Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000000420 anogeissus latifolia wall. gum Substances 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- OISFUZRUIGGTSD-LJTMIZJLSA-N azane;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound N.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO OISFUZRUIGGTSD-LJTMIZJLSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005870 benzindolyl group Chemical group 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 108010063132 birinapant Proteins 0.000 description 1
- 229950004237 birinapant Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229960005338 clevudine Drugs 0.000 description 1
- GBBJCSTXCAQSSJ-XQXXSGGOSA-N clevudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1[C@H](F)[C@@H](O)[C@H](CO)O1 GBBJCSTXCAQSSJ-XQXXSGGOSA-N 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 229940126545 compound 53 Drugs 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- 229940126179 compound 72 Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940096516 dextrates Drugs 0.000 description 1
- 239000008355 dextrose injection Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000005046 dihydronaphthyl group Chemical group 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- WEHWNAOGRSTTBQ-UHFFFAOYSA-N dipropylamine Chemical compound CCCNCCC WEHWNAOGRSTTBQ-UHFFFAOYSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229950006528 elvucitabine Drugs 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000006345 epimerization reaction Methods 0.000 description 1
- XBRDBODLCHKXHI-UHFFFAOYSA-N epolamine Chemical compound OCCN1CCCC1 XBRDBODLCHKXHI-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- FYZZJDABXBPMOG-UHFFFAOYSA-N ethanol;n-methylmethanamine Chemical compound CCO.CNC FYZZJDABXBPMOG-UHFFFAOYSA-N 0.000 description 1
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 235000019314 gum ghatti Nutrition 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 239000008173 hydrogenated soybean oil Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000005990 isobenzothienyl group Chemical group 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229940059904 light mineral oil Drugs 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- YGBMCLDVRUGXOV-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 YGBMCLDVRUGXOV-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 125000003518 norbornenyl group Chemical group C12(C=CC(CC1)C2)* 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000003544 oxime group Chemical group 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Chemical group O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229940070687 psyllium Drugs 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000012748 slip agent Substances 0.000 description 1
- 229940075439 smac mimetic Drugs 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- CMIBWIAICVBURI-SSDOTTSWSA-N tert-butyl (3r)-3-aminopyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC[C@@H](N)C1 CMIBWIAICVBURI-SSDOTTSWSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000000165 tricyclic carbocycle group Chemical group 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229950003036 vesatolimod Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 1
- 229940007718 zinc hydroxide Drugs 0.000 description 1
- 229910021511 zinc hydroxide Inorganic materials 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
技术领域
本发明公开涉及苯基-甲酰胺衍生物、其药物组合物及其在治疗B型肝炎中的用途。
背景技术
B型肝炎病毒(HBV)会引起肝脏炎症和损伤,而且在几十年内亦可能进一步导致严重并发症,包括肝硬化和肝细胞癌。B型肝炎是重大的公共卫生威胁,全世界有超过2.5亿人患有B型肝炎,每年将近一百万人死于B型肝炎和相关疾病。
HBV是具有二十面体核心的包膜DNA病毒。核心蛋白质壳(衣壳;Capsid)是120个核心蛋白质同源二聚体的自组装复合物。核心蛋白质正确组装成结构上和功能上相符的形式是成功进行生物学过程的关键步骤。衣壳包围HBV DNA和具有逆转录酶活性的DNA聚合酶。HBV的复制高度依赖于衣壳的准确组装,而衣壳也与造成持续感染的共价闭合环状DNA(cccDNA)累积相关。除了衣壳组装外,核心蛋白质在HBV生命周期中也具有多种作用,使其成为具有吸引力的药物靶标
干扰素(IFNs)和核苷酸类似物(NAs)是目前可用于治疗慢性HBV感染的药物。但是,这些当前可用的治疗药物并没办法治愈HBV感染。因此,可有效用于治疗和/或预防HBV感染的新型化合物在本领域中仍是有需要的。
发明内容
本公开涉及一种B型肝炎病毒抑制剂的苯基-甲酰胺衍生物,这些衍生物显示出优异的抗HBV活性及出乎意料的有利特性。
本文提供以下式(I)的化合物、其药学上可接受的盐、立体异构体、溶剂合物或前药:
式中,Ra、Rb、Rc和Rd中的每一个独立地是氢、卤素、CN、OH、C1-6烷基、C2-6烯基或C1-6烷氧基,其中,C1-6烷基、C2-6烯基或C1-6烷氧基可各自任选地被1至4个卤素、OH或CN所取代;
X1和X2中的每一个独立地是C或N;
R1和R2中的每一个独立地是氢、CN、OH、卤素、C1-6烷基、C1-6烷氧基、C2-6烯基、C3-12碳环基、C3-12杂环基、芳基或C5-14杂芳基,其中,C1-6烷基、C1-6烷氧基、C2-6烯基、C3-12碳环基、C3-12杂环基、芳基或C5-14杂芳基可各自任选地被1至4个氘、卤素、OH、CN、C1-6烷基、C1-6烷氧基或C3-12碳环基所取代;
R3是氢、卤素或可任选地被1至4个氘或卤素所取代的C1-6烷基;
或是R1和R3可与其邻接的原子一起形成C3-12碳环基、C3-12杂环基或C5-14杂芳基,其中,C3-12碳环基、C3-12杂环基或C5-14杂芳基可各自任选地被1至4个卤素、OH、CN、NH2、C1-6烷基、C2-6烯基、C1-6烷氧基、C3-12碳环基、C3-12杂环基、芳基或C5-14杂芳基所取代;
W不存在或可为NR5;
R5是氢或可任选地被1至4个卤素所取代的C1-6烷基;
Z是C3-12杂环基、C3-12碳环基、C1-6烷基(C3-12碳环基)或C1-6烷基(C3-12杂环基),其中,C3-12杂环基、C3-12碳环基、C1-6烷基(C3-12碳环基)或C1-6烷基(C3-12杂环基)可各自任选地被1至4个卤素、CN、可任选地被1至4个卤素所取代的C1-6烷基或是可任选地被1至4个卤素所取代的C1-6烷氧基所取代;
L是-S(O)2-、-NHS(O)2-、-S(O)2NH-、-NHS(O)2NH-、-S(O)2N(CH3)-、-NHS(O)2N(CH3)-、-(C=O)2-、-NH(C=O)-、-NH(C=O)NH-、-NH(C=O)2-、-(C=O)2NH-、-NH(C=O)2NH-、-(C=O)2N(CH3)-或-NH(C=O)2N(CH3)-;
R4是氢、C1-6烷基、C2-6烯基、C2-6炔基、C1-6烷氧基、C3-12碳环基、C3-12杂环基、芳基或C5-14杂芳基,其中,C1-6烷基、C2-6烯基、C2-6炔基、C1-6烷氧基、C3-12碳环基、C3-12杂环基、芳基或C5-14杂芳基可各自任选地被1至4个卤素、OH、CN、羧基、C1-6烷基、C1-6烷氧基、C3-12碳环基、C3-12杂环基、芳基或C5-14杂芳基所取代;
式中环内的虚线表示单键或双键;
此外,条件是当L为-S(O)2-时,R4不是C1-6烷基。
本公开还提供了药物组合物,其包含本文公开的化合物,例如式(I)的化合物,包括其立体异构体、其对映异构体、其药学上可接受的盐、溶剂合物或其前药,和一个或多个药学上可接受的载体或赋形剂。该药物组合物可用于治疗HBV感染或与HBV有关的疾病。
本公开还提供了一种治疗、预防或改善个体HBV感染或HBV介导的病症、疾病或一个或多个症状的方法,包括向个体施用治疗有效量的本文公开的化合物,例如式(I)的化合物,包括其立体异构体、其对映异构体、其药学上可接受的盐、溶剂合物或其前药。在相关的实施例中,该方法可以进一步包括给予本文公开的化合物(例如式(I)的化合物,包括其立体异构体、其对映异构体、其药学上可接受的盐、溶剂合物或其前药)以及与一个或多个其他治疗剂的组合,其中,本文公开的化合物和一个或多个其他治疗剂的组合可以以单一制剂的形式一起施用,或以不同的制剂形式分别施用,此外,本文公开的化合物和其他治疗剂可以是同时或依次进行给药的。
本公开另外提供了制备本文公开的化合物(例如式(I)的化合物,包括其立体异构体、其对映异构体、其药学上可接受的盐、溶剂合物或其前药)的方法。
具体实施方式
为便于理解本文所阐述的发明内容,下文定义多个术语。
一般而言,本文所用的命名法及本文所描述的有机化学、药物化学及药理学中的实验室程序为熟知且常用于此项技术中的命名法及实验室程序。除非另外定义,否则本文所用的所有技术及科学术语一般具有与本发明所属领域的普通技术人员通常所理解相同的含义。
术语“约”将被本领域的普通技术人员理解,并且将在使用它的上下文中有所变化。如本文所使用,当涉及诸如量、期间等可测量的数值时,术语“约”意在包括±20%或±10%的变化,包括±5%、±1%或相对于既定值的±0.1%范围,这样的变化适合于所公开的方法。
术语“治疗”是指包括缓解或消除病症、疾病或与该病症、疾病或病状相关联的一个或多个症状;或缓解或根除该病症、疾病或症状本身的起因。
术语“预防”是指包括一种实现以下目的的方法:推迟和/或排除病症、疾病或病状和/或其伴随症状的发作;防止个体罹患病症、疾病或病状;或降低个体罹患病症、疾病或病状的风险。
术语“患者”、“个体”或“受试者”是指人类或非人类的哺乳动物。在一个实施例中,患者、个体或受试者为人类。
术语“治疗有效量”是指包括在投与时足以防止所治疗的病症、疾病或病状的一或多种症状的发展或在一定程度上减轻该一或多种症状的活性化合物的量。
术语“药学上可接受的载体”或“药学上可接受的赋形剂”系指药学上可接受的材料、组合物或媒剂,诸如液体或固体填充剂、稀释剂、溶剂或包封材料,其不会消除活性化合物的生物活性或特性,并且是相对无毒的,亦即,可以将该材料施用于个体而不会引起不良的生物学效应或以有害的方式与组合物中的任何组分相互作用。参见Remington:TheScience and Practice of Pharmacy,第21版;Lippincott Williams&Wilkins:Philadelphia,PA,2005;Handbook of Pharmaceutical Excipients,第6版;Rowe等人编;The Pharmaceutical Press and the American Pharmaceutical Association:2009;Handbook of Pharmaceutical Additives,第3版,Ash及Ash编;Gower PublishingCompany:2007;Pharmaceutical Preformulation and Formulation,第2版,Gibson编;CRCPress LLC:Boca Raton,FL,2009。
术语“一个或多个(一种或多种)”是指一个或大于一的个数(例如2、3、4、5、6或7)。
术语“卤素”或“卤代”(可单独或作为其他取代基的一部分)是指氟、氯、溴或碘原子。
术语“羧基”是指–C(=O)OR’,其中R’是氢、C1-6烷基、C3-12环烷基、C2-6烯基、C3-12环烯基、C2-6炔基、芳基(例如芐基)或C5-14杂芳基。
术语“C1-6烷基”(可单独或作为其他取代基的一部分)是指含有1至6个(例如1至4个、1至3个)碳原子的具支链或直链单价饱和脂肪族烃基团。C1-6烷基的实例包含甲基、乙基、正丙基、异丙基、正丁基、异丁基、第二丁基、第三丁基、正戊基及诸如此类基团。
术语“C2-6烯基”(可单独或作为其他取代基的一部分)是指含有2至6个(例如2至4个、2至3个)碳原子和一个或多个烯烃键的直链或具支链烃基团,C2-6烯基之实例包含乙烯基、烯丙基、丙烯基、异丙烯基、丁烯基、异丁烯基、异戊二烯基、丁二烯基、戊烯基、异戊烯基、戊二烯基及诸如此类基团。
术语“C2-6炔基”(可单独或作为其他取代基的一部分)是指含有2至6个(例如2至4个、2至3个)碳原子和一个或多个炔烃键的直链或具支链烃基团,C2-6炔基之实例包含乙炔基、丙炔基、丁炔基、戊炔基及诸如此类基团。
术语“C1-6烷氧基”(可单独或作为其他取代基的一部分)是指基团-OR”,其中R”是C1-6烷基,C1-6烷氧基的实例包含甲氧基、乙氧基、正丙氧基、异丙氧基、正丁氧基、异丁氧基、仲丁氧基或叔丁氧基。
术语“碳环基”(可单独或作为其他取代基的一部分)是指含有3至12个碳环原子(C3-12)的饱和(即“环烷基”)或部分不饱和(即“环烯基”)单环或双环(包括稠合、桥接或螺环)。在某些实施例中,碳环基具有3至10个(C3-10)、3至8个(C3-8)、4至8个(C4-8)、3至6个(C3-6)、4至6个(C4-6)或5至6个(C5-6)碳环原子。此类碳环基的实例包含但不限于环丙基、环丁基、环戊基、环戊烯基、环己基、环己烯基、环庚基、降冰片基(norbornyl)和降冰片烯基(norbornenyl)。
术语“杂环基”是指含有3至12个环原子(C3-12)的饱和(即“杂环烷基”)或部分不饱和(即“杂环烯基”)单环或双环(包括稠合、桥接或螺环),其中,杂环基包含1、2或3个独立地选自O、S和N的杂原子。在某些实施例中,杂环基具有3至10个(C3-10)、3至8个(C3-8)、4至8个(C4-8)、3至6个(C3-6)、4至6个(C4-6)或5至6个(C5-6)环原子。杂环基可在任何引起产生稳定化合物之杂原子或碳原子处连接至主结构。此类杂环基的实例包括但不限于氮杂环丁烷基、吡咯烷基、哌啶基、哌嗪基、吗啉基、氧杂环丁烷基、四氢吡喃基、四氢吡喃基和四氢呋喃基。
术语“芳基”是指含有至少一个芳族碳环之单价单环芳族基及/或单价多环芳族基。在某些实施例中,芳基具有6至20个(C6-20)、6至14个(C6-14)或6至10个(C6-10)环原子。芳基之实例包括但不限于苯基、萘基、芴基、薁基、蒽基、菲基、芘基、联苯及三联苯。芳基亦指双环或三环碳环,其中环中之一者为芳族且其他环可为饱和、部分不饱和或芳族,例如二氢萘基、茚基、二氢茚基(indanyl)或四氢萘基(萘满基)。
术语“杂芳基”是指含有至少一个芳环之单价单环芳族基或单价多环芳族基,其中至少一个芳环在环中含有1、2、3或4个独立地选自O、S及N之杂原子。杂芳基经由芳环键结至分子之其余部分。杂芳基之各环可含有1个或2个O原子、一个或2个S原子或一至4个N原子,其限制条件为各环中之杂原子的总数为4个或4个以下且各环含有至少一个碳原子。在某些实施例中,杂芳基具有5至20个(C5-20)、5至14个(C5-14)或5至10个(C5-10)环原子。单环杂芳基之实例包括但不限于呋喃基、咪唑基、异噻唑基、异噁唑基、噁二唑基、噁唑基、吡嗪基、吡唑基、哒嗪基、吡啶基、嘧啶基、吡咯基、噻二唑基、噻唑基、噻吩基、四唑基、三嗪基及***基。双环杂芳基之实例包括但不限于苯并呋喃基、苯并咪唑基、苯并异噁唑基、苯并哌喃基、苯并噻二唑基、苯并噻唑基、苯并噻吩基、苯并***基、苯并噁唑基、呋喃并吡啶基、咪唑并吡啶基、咪唑并噻唑基、吲哚嗪基、吲哚基、吲唑基、异苯并呋喃基、异苯并噻吩基、异吲哚基、异喹啉基、异噻唑基、萘啶基、噁唑并吡啶基、酞嗪基、蝶啶基、嘌呤基、吡啶并吡啶基、吡咯并吡啶基、喹啉基、喹喔啉基、喹唑啉基、噻二唑并嘧啶基及噻吩并吡啶基。三环杂芳基之实例包括但不限于吖啶基、苯并吲哚基、咔唑基、二苯并呋喃基、萘嵌间二氮杂苯基、菲咯啉基、菲啶基、砷氮杂蒽基、吩嗪基、吩噻嗪基、吩噁嗪基及氧蒽基。
术语“氨基保护基”是指与氨基连接并且在一定条件下容易除去的化学基团。它包括但不限于烷氧羰基、酰基或烷基;保护基的实例包括但不限于叔丁氧羰基、芐氧羰基、芴-甲氧羰基、烯丙氧羰基、邻苯二甲酰基、芐基、对甲氧基芐基或三苯甲基等。本领域之一般熟习此项技术者可以参考本领域的常规教科书,例如Greene's Protective Groups inOrganic Synthesis(第四版),适当地选择和操纵。
术语“溶剂合物”是指活性化合物和药学上可接受的溶剂所形成的络合物。药学上可接受的溶剂的实例包括但不限于水、乙醇、异丙醇、乙酸乙酯、乙酸和乙醇胺。
本文的公开内容涉及式(I)的化合物、药学上可接受的盐、立体异构体、溶剂合物或其前药:
其中,
Ra、Rb、Rc和Rd中的每一个独立地是氢、卤素、CN、OH、C1-6烷基、C2-6烯基或C1-6烷氧基,其中,C1-6烷基、C2-6烯基或C1-6烷氧基可各自任选地被1至4个卤素、OH或CN所取代;
X1和X2中的每一个独立地是C或N;
R1和R2中的每一个独立地是氢、CN、OH、卤素、C1-6烷基、C1-6烷氧基、C2-6烯基、C3-12碳环基、C3-12杂环基、芳基或C5-14杂芳基,其中,C1-6烷基、C1-6烷氧基、C2-6烯基、C3-12碳环基、C3-12杂环基、芳基或C5-14杂芳基可各自任选地被1至4个氘、卤素、OH、CN、C1-6烷基、C1-6烷氧基或C3-12碳环基所取代;
R3是氢、卤素或可任选地被1至4个氘或卤素所取代的C1-6烷基;
或是R1和R3可与其邻接的原子一起形成C3-12碳环基、C3-12杂环基或C5-14杂芳基,其中,C3-12碳环基、C3-12杂环基或C5-14杂芳基可各自任选地被1至4个卤素、OH、CN、NH2、C1-6烷基、C2-6烯基、C1-6烷氧基、C3-12碳环基、C3-12杂环基、芳基或C5-14杂芳基所取代;
W不存在或可为NR5;
R5是氢或可任选地被1至4个卤素所取代的C1-6烷基;
Z是C3-12杂环基、C3-12碳环基、C1-6烷基(C3-12碳环基)或C1-6烷基(C3-12杂环基),其中,C3-12杂环基、C3-12碳环基、C1-6烷基(C3-12碳环基)或C1-6烷基(C3-12杂环基)可各自任选地被1至4个卤素、CN、可任选地被1至4个卤素所取代的C1-6烷基或是可任选地被1至4个卤素所取代的C1-6烷氧基所取代;
L是-S(O)2-、-NHS(O)2-、-S(O)2NH-、-NHS(O)2NH-、-S(O)2N(CH3)-、-NHS(O)2N(CH3)-、-(C=O)2-、-NH(C=O)-、-NH(C=O)NH-、-NH(C=O)2-、-(C=O)2NH-、-NH(C=O)2NH-、-(C=O)2N(CH3)-或-NH(C=O)2N(CH3)-;
R4是氢、C1-6烷基、C2-6烯基、C2-6炔基、C1-6烷氧基、C3-12碳环基、C3-12杂环基、芳基或C5-14杂芳基,其中,C1-6烷基、C2-6烯基、C2-6炔基、C1-6烷氧基、C3-12碳环基、C3-12杂环基、芳基或C5-14杂芳基可各自任选地被1至4个卤素、OH、CN、羧基、C1-6烷基、C1-6烷氧基、C3-12碳环基、C3-12杂环基、芳基或C5-14杂芳基所取代;
式中环内的虚线表示单键或双键;
此外,条件是当L为-S(O)2-时,R4不是C1-6烷基。
在另一个实施例中,本文涉及式(II)的化合物、药学上可接受的盐、立体异构体、溶剂合物或其前药:
其中,
Ra、Rb、Rc和Rd中的每一个独立地是氢、卤素、CN、OH、C1-6烷基、C2-6烯基或C1-6烷氧基,其中,C1-6烷基、C2-6烯基或C1-6烷氧基可各自任选地被1至4个卤素、OH或CN所取代;
R1和R2中的每一个独立地是氢、CN、OH、卤素、C1-6烷基、C1-6烷氧基、C2-6烯基、C3-12碳环基、C3-12杂环基、芳基或C5-14杂芳基,其中,C1-6烷基、C1-6烷氧基、C2-6烯基、C3-12碳环基、C3-12杂环基、芳基或C5-14杂芳基可各自任选地被1至4个氘、卤素、OH、CN、C1-6烷基、C1-6烷氧基或C3-12碳环基所取代;
R3是氢、卤素或可任选地被1至4个氘或卤素所取代的C1-6烷基;
或是R1和R3可与其邻接的原子一起形成C3-12碳环基、C3-12杂环基或C5-14杂芳基,其中,C3-12碳环基、C3-12杂环基或C5-14杂芳基可各自任选地被1至4个卤素、OH、CN、NH2、C1-6烷基、C2-6烯基、C1-6烷氧基、C3-12碳环基、C3-12杂环基、芳基或C5-14杂芳基所取代;
W不存在或可为NR5;
R5是氢或可任选地被1至4个卤素所取代的C1-6烷基;
Z是C3-12杂环基、C3-12碳环基、C1-6烷基(C3-12碳环基)或C1-6烷基(C3-12杂环基),其中,C3-12杂环基、C3-12碳环基、C1-6烷基(C3-12碳环基)或C1-6烷基(C3-12杂环基)可各自任选地被1至4个卤素、CN、可任选地被1至4个卤素所取代的C1-6烷基或是可任选地被1至4个卤素所取代的C1-6烷氧基所取代;
L是-S(O)2-、-NHS(O)2-、-S(O)2NH-、-NHS(O)2NH-、-S(O)2N(CH3)-、-NHS(O)2N(CH3)-、-(C=O)2-、-NH(C=O)-、-NH(C=O)NH-、-NH(C=O)2-、-(C=O)2NH-、-NH(C=O)2NH-、-(C=O)2N(CH3)-或-NH(C=O)2N(CH3)-;
R4是氢、C1-6烷基、C2-6烯基、C2-6炔基、C1-6烷氧基、C3-12碳环基、C3-12杂环基、芳基或C5-14杂芳基,其中,C1-6烷基、C2-6烯基、C2-6炔基、C1-6烷氧基、C3-12碳环基、C3-12杂环基、芳基或C5-14杂芳基可各自任选地被1至4个卤素、OH、CN、羧基、C1-6烷基、C1-6烷氧基、C3-12碳环基、C3-12杂环基、芳基或C5-14杂芳基所取代;
此外,条件是当L为-S(O)2-时,R4不是C1-6烷基。
在另一个实施例中,本文还涉及式(III)的化合物、其药学上可接受的盐、立体异构体、溶剂合物或其前药:
其中,
Ra、Rb、Rc和Rd中的每一个独立地是氢、卤素、CN、OH、C1-6烷基、C2-6烯基或C1-6烷氧基,其中,C1-6烷基、C2-6烯基或C1-6烷氧基可各自任选地被1至4个卤素、OH或CN所取代;
R2是氢、CN、OH、卤素、C1-6烷基、C1-6烷氧基、C2-6烯基、C3-12碳环基、C3-12杂环基、芳基或C5-14杂芳基,其中,C1-6烷基、C1-6烷氧基、C2-6烯基、C3-12碳环基、C3-12杂环基、芳基或C5-14杂芳基可各自任选地被1至4个氘、卤素、OH、CN、C1-6烷基或C1-6烷氧基所取代;
是含有1或2个氮原子的C3-12杂环基,其中,该杂环基可任选地被1至4个卤素、OH、CN、NH2、C1-6烷基、C2-6烯基、C1-6烷氧基、C3-12碳环基、C3-12杂环基、芳基或C5-14杂芳基所取代;在一实施例中,是含有1个氮原子的C4-8杂环基,其中,该杂环基可任选地被1至4个卤素、OH、CN、C1-6烷基、C2-6烯基或C1-6烷氧基所取代;在另一个实施例中,是 其中,这些杂环基可各自任选地被1至4个卤素、OH、CN、C1-6烷基、C2-6烯基或C1-6烷氧基所取代;在其他实施例中,是其中,该等杂环基可各自任选地被1至4个卤素、OH、CN、C1-6烷基、C2-6烯基或C1-6烷氧基所取代;
W不存在或可为NR5;
R5是氢或可任选地被1至4个卤素所取代的C1-6烷基;
Z是C3-12杂环基、C3-12碳环基、C1-6烷基(C3-12碳环基)或C1-6烷基(C3-12杂环基),其中,C3-12杂环基、C3-12碳环基、C1-6烷基(C3-12碳环基)或C1-6烷基(C3-12杂环基)可各自任选地被1至4个卤素、CN、可任选地被1至4个卤素所取代的C1-6烷基或是可任选地被1至4个卤素所取代的C1-6烷氧基所取代;
L是-S(O)2-、-NHS(O)2-、-S(O)2NH-、-NHS(O)2NH-、-S(O)2N(CH3)-、-NHS(O)2N(CH3)-、-(C=O)2-、-NH(C=O)-、-NH(C=O)NH-、-NH(C=O)2-、-(C=O)2NH-、-NH(C=O)2NH-、-(C=O)2N(CH3)-或-NH(C=O)2N(CH3)-;
R4是氢、C1-6烷基、C2-6烯基、C2-6炔基、C1-6烷氧基、C3-12碳环基、C3-12杂环基、芳基或C5-14杂芳基,其中,C1-6烷基、C2-6烯基、C2-6炔基、C1-6烷氧基、C3-12碳环基、C3-12杂环基、芳基或C5-14杂芳基可各自任选地被1至4个卤素、OH、CN、羧基、C1-6烷基、C1-6烷氧基、C3-12碳环基、C3-12杂环基、芳基或C5-14杂芳基所取代;
此外,条件是当L为-S(O)2-时,R4不是C1-6烷基。
在其他实施例中,本文还涉及式(IV)的化合物、其药学上可接受的盐、立体异构体、溶剂合物或其前药:
其中,
Ra、Rb、Rc和Rd中的每一个独立地是氢、卤素、CN、OH、C1-6烷基、C2-6烯基或C1-6烷氧基,其中,C1-6烷基、C2-6烯基或C1-6烷氧基可各自任选地被1至4个卤素、OH或CN所取代;
R1和R2中的每一个独立地是氢、CN、OH、卤素、C1-6烷基、C1-6烷氧基、C2-6烯基、C3-12碳环基、C3-12杂环基、芳基或C5-14杂芳基,其中,C1-6烷基、C1-6烷氧基、C2-6烯基、C3-12碳环基、C3-12杂环基、芳基或C5-14杂芳基可各自任选地被1至4个氘、卤素、OH、CN、C1-6烷基、C1-6烷氧基或C3-12碳环基所取代;
R3是氢、卤素或可任选地被1至4个氘或卤素所取代的C1-6烷基;
或是R1和R3可与其邻接的原子一起形成C3-12碳环基、C3-12杂环基或C5-14杂芳基,其中,C3-12碳环基、C3-12杂环基或C5-14杂芳基可各自任选地被1至4个卤素、OH、CN、NH2、C1-6烷基、C2-6烯基、C1-6烷氧基、C3-12碳环基、C3-12杂环基、芳基或C5-14杂芳基所取代;
R5是氢或可任选地被1至4个卤素所取代的C1-6烷基;
是含有1或2个氮原子的C3-12杂环基,其中,该杂环基可任选地被1至4个卤素或可任选地被1至4个卤素所取代的C1-6烷基所取代;在一实施例中,是含有1或2个氮原子的C4-8杂环基,其中,该杂环基可任选地被1至4个卤素或可任选地被1至4个卤素所取代的C1-6烷基所取代;在另一个实施例中,是含有1个氮原子的C4-8杂环基,其中,该杂环基可任选地被1至4个卤素或可任选地被1至4个卤素所取代的C1-6烷基所取代;在另一个实施例中,是 其中,这些杂环基可各自任选地被1至4个卤素或可任选地被1至4个卤素所取代的C1-6烷基所取代;在其他实施例中,是 其中,这些杂环基可各自任选地被1至4个卤素或可任选地被1至4个卤素所取代的C1-6烷基所取代;
L是-S(O)2-、-NHS(O)2-、-S(O)2NH-、-NHS(O)2NH-、-S(O)2N(CH3)-、-NHS(O)2N(CH3)-、-(C=O)2-、-NH(C=O)-、-NH(C=O)NH-、-NH(C=O)2-、-(C=O)2NH-、-NH(C=O)2NH-、-(C=O)2N(CH3)-或-NH(C=O)2N(CH3)-;
R4是氢、C1-6烷基、C2-6烯基、C2-6炔基、C1-6烷氧基、C3-12碳环基、C3-12杂环基、芳基或C5-14杂芳基,其中,C1-6烷基、C2-6烯基、C2-6炔基、C1-6烷氧基、C3-12碳环基、C3-12杂环基、芳基或C5-14杂芳基可各自任选地被1至4个卤素、OH、CN、羧基、C1-6烷基、C1-6烷氧基、C3-12碳环基、C3-12杂环基、芳基或C5-14杂芳基所取代;
此外,条件是当L为-S(O)2-时,R4不是C1-6烷基。
以下的实施例包括在式(I)、(II)、(III)及/或(IV)化合物的定义内。
在一实施例中,Ra、Rb、Rc和Rd中的每一个独立地是氢、卤素、CN或可任选地被1至4个卤素所取代的C1-6烷基;在另一个实施例中,Ra、Rb、Rc和Rd中的每一个独立地是氢、卤素、CN或可任选地被1至4个氟所取代的C1-6烷基;在另一个实施例中,Ra、Rb、Rc和Rd中的每一个独立地是氢、氟、氯、溴、CN或可任选地被1至4个氟所取代的C1-6烷基。
在一实施例中,R1和R2中的每一个独立地是氢、CN、卤素、C1-6烷基、C2-6烯基或C3-12碳环基,其中,C1-6烷基、C2-6烯基或C3-12碳环基可各自任选地被1至4个卤素、CN、C1-6烷基或C3-12碳环基所取代;在另一个实施例中,R1和R2中的每一个独立地是氢、卤素、C1-6烷基、C2-6烯基或C3-12碳环基,其中,C1-6烷基、C2-6烯基或C3-12碳环基可各自任选地被1至4个卤素或C3-12碳环基所取代;在另一个实施例中,R1和R2中的每一个独立地是氢、氟、氯、溴、C1-6烷基、C2-6烯基或C3-12碳环基,其中,该C1-6烷基可任选地被1至4个卤素或C3-6碳环基所取代。
在一实施例中,R1是氢、CN、卤素、C1-6烷基、C2-6烯基或C3-12碳环基,其中,C1-6烷基、C2-6烯基或C3-12碳环基可各自任选地被1至4个卤素、CN或C3-12碳环基所取代;在另一个实施例中,R1是氢、卤素、C1-6烷基或C2-6烯基,其中,C1-6烷基或C2-6烯基可各自任选地被1至4个卤素或C3-12碳环基所取代;在另一个实施例中,R1是氢、氟、氯、溴、C1-6烷基或C2-6烯基,其中,C1-6烷基或C2-6烯基可各自任选地被1至4个卤素或C3-6碳环基所取代。
在一实施例中,R2是氢、CN、卤素或可任选地被1至4个氟所取代的C1-6烷基;在另一个实施例中,R2是氢、氟、氯、溴或C1-6烷基;在另一个实施例中,R2是氟、氯或溴。
在一实施例中,R3是氢、卤素或可任选地被1至4个卤素所取代的C1-6烷基;在另一个实施例中,R3是氢、卤素或可任选地被1至4个氟所取代的C1-6烷基;在另一个实施例中,R3是氢、氟、氯、溴或可任选地被1至4个氟所取代的C1-6烷基。
在一实施例中,R1和R3可与其邻接的原子一起形成可任选地被1至4个卤素、CN或C1-6烷基所取代的C3-12杂环基;在另一个实施例中,R1和R3可与其邻接的原子一起形成可任选地被1至4个卤素、CN或C1-6烷基所取代的C5-6杂环基;在另一个实施例中,R1和R3可与其邻接的原子一起形成吡咯烷或哌啶,其中,该吡咯烷或哌啶可任选地被1至4个卤素、CN或C1-6烷基所取代。
在一实施例中,W是NR5,其中,R5是氢或可任选地被1至4个卤素所取代的C1-6烷基;在另一个实施例中,W是NR5,其中,R5是氢。
在一实施例中,Z是C3-12杂环基或C3-12碳环基,其中,该C3-12杂环基或C3-12碳环基可各自任选地被1至4个卤素、CN或可任选地被1至4个卤素所取代的C1-6烷基所取代;在另一个实施例中,Z是含有1或2个氮原子的C3-12杂环基,或是C3-12碳环基,其中,该C3-12杂环基或C3-12碳环基可各自任选地被1至4个卤素、CN或可任选地被1至4个卤素所取代的C1-6烷基所取代;在另一个实施例中,Z是含有1或2个氮原子的C4-8杂环基,其中,该C4-8杂环基可任选地被1至4个卤素或可任选地被1至4个卤素所取代的C1-6烷基所取代;在其他实施例中,Z是含有1或2个氮原子的C4-8杂环基,其中,该C4-8杂环基可任选地被1至4个卤素所取代,而且该C4-8杂环基上的氮原子会与L连接。
在一实施例中,Z是 其中,这些杂环基可各自任选地被1至4个卤素或可任选地被1至4个卤素所取代的C1-6烷基所取代;在另一个实施例中,Z是 其中,这些杂环基可各自任选地被1至4个卤素或可任选地被1至4个卤素所取代的C1-6烷基所取代;在另一个实施例中,Z是 其中,这些杂环基可各自任选地被1至4个卤素或可任选地被1至4个卤素所取代的C1-6烷基所取代。
在一实施例中,L是-S(O)2-、-S(O)2NH-、-S(O)2N(CH3)-、-NHS(O)2NH-、-(C=O)2NH-或-NH(C=O)2NH-;在另一个实施例中,L是-S(O)2NH-、-S(O)2N(CH3)-、-(C=O)2NH-或-NH(C=O)2NH-;在另一个实施例中,L是-S(O)2NH-或-S(O)2N(CH3)-;在其他实施例中,L是-(C=O)2-、-NH(C=O)-、-NH(C=O)NH-、-NH(C=O)2-、-(C=O)2NH-、-NH(C=O)2NH-、-(C=O)2N(CH3)-或-NH(C=O)2N(CH3)-;在其他实施例中,L是-(C=O)2-、-NH(C=O)2-、-(C=O)2NH-、-NH(C=O)2NH-、-(C=O)2N(CH3)-或-NH(C=O)2N(CH3)-;在其他实施例中,L是(C=O)2NH-或-NH(C=O)2NH-。
在一实施例中,R4是氢、C1-6烷基、C2-6烯基、C1-6烷氧基、C3-12碳环基、C3-12杂环基、芳基或C5-14杂芳基,其中,C1-6烷基、C2-6烯基、C1-6烷氧基、C3-12碳环基、C3-12杂环基、芳基或C5-14杂芳基可各自任选地被1至4个卤素、OH、CN、羧基、C1-6烷基、C1-6烷氧基或芳基所取代;在另一个实施例中,R4是氢、C1-6烷基、C2-6烯基、C1-6烷氧基、C3-12碳环基、C3-12杂环基或芳基,其中,C1-6烷基、C2-6烯基、C1-6烷氧基、C3-12碳环基、C3-12杂环基或芳基可各自任选地被1至4个卤素、CN、羧基、C1-6烷基、C1-6烷氧基或芳基所取代。
在一实施例中,本文所公开的化合物选自下组:
,或其药学上可接受的盐、立体异构体,溶剂合物或前药。
除非指定特定立体化学,否则本文所提供的化合物意欲涵盖所有可能的立体异构体。当本文所提供的化合物含有烯基或亚烯基时,化合物可以一种几何顺式/反式(或Z/E)异构体形式存在或以其混合物形式存在。当结构异构体可经由低能量障壁相互转化时,化合物可以单一互变异构体形式或互变异构体的混合物形式存在。此在含有例如亚胺基、酮基或肟基的化合物中可呈质子互变异构形式;或在含有芳族部分的化合物中呈所谓的价互变异构形式。由此得出结论:单一化合物可呈现一种以上类型的异构现象。
本文所提供的化合物可为对映异构纯的,诸如单一对映异构体或单一非对映异构体或立体异构混合物,诸如对映异构体混合物、外消旋混合物或非对映异构体混合物。因而,本领域普通技术人员应认识到对于经历活体内差向异构化反应的化合物而言,给药呈(R)形式的化合物与给药呈(S)形式的化合物等效。制备/分离个别对映异构体的常规技术包括自适合光学纯前驱体合成、自手性起始物质不对称合成或拆分对映异构体混合物,例如手性色谱、再结晶、拆分、非对映异构盐形成或在衍生成非对映异构加合物后分离。
当本文提供的化合物包含酸性或碱性部分时,它也可以作为药学上可接受的盐提供。药学上可接受的盐通常由药学上可接受的无毒碱或酸(包括无机或有机碱以及无机或有机酸)制备。适用于制备药学上可接受的盐的酸包括但不限于乙酸盐、抗坏血酸盐、己二酸盐、海藻酸盐、天冬氨酸盐、苯磺酸盐、苯甲酸盐、碳酸氢盐、硫酸氢盐、酒石酸氢盐、硼酸盐、溴化物、丁酸盐、樟脑酸盐、樟脑磺酸盐、右旋樟脑磺酸盐、碳酸盐、氯化物、克拉维酸盐(clavulanate)、柠檬酸盐、环戊烷丙酸盐、二乙基乙酸、二葡萄糖酸盐、二盐酸盐、十二烷基磺酸盐、依地酸盐、乙二磺酸盐、依托酸盐(estolate)、乙磺酸盐、乙烷磺酸盐、甲酸盐、富马酸盐、葡庚糖酸盐、葡庚酸盐、葡萄糖酸盐、谷氨酸盐、甘油磷酸盐、对羟乙酰胺基苯胂酸盐(glycollylarsanilate)、半硫酸盐、庚酸盐、己酸盐、己基间苯二酚盐、哈胺(hydrabamine)、氢溴酸盐、盐酸盐、2-羟基乙烷磺酸盐、羟基萘甲酸盐、碘化物、异烟碱酸盐、羟乙磺酸盐、乳酸盐、乳糖酸盐、月桂酸盐、苹果酸盐、马来酸盐、扁桃酸盐、甲磺酸盐、甲基溴化物、甲基硝酸盐、甲基硫酸盐、甲烷磺酸盐、黏酸盐、2-萘磺酸盐、萘磺酸盐、烟碱酸盐、硝酸盐、N-甲基葡萄糖胺铵盐、油酸盐、草酸盐、双羟萘酸盐(恩波酸盐(embonate))、棕榈酸盐、泛酸盐、果冻酸盐、过硫酸盐、磷酸盐/磷酸氢盐、庚二酸盐、苯基丙酸盐、聚半乳糖醛酸盐、丙酸盐、柳酸盐、硬脂酸盐、硫酸盐、次乙酸盐、琥珀酸盐、鞣酸盐、酒石酸盐、茶氯酸盐、硫氰酸盐、甲苯磺酸盐(tosylate)、三乙碘化物、三氟乙酸盐、十一酸盐、戊酸盐及诸如此类。适用于制备药学上可接受的盐的碱包括但不限于氢氧化镁、氢氧化钙、氢氧化钾、氢氧化锌或氢氧化钠;及有机碱,诸如第一、第二、第三及四级、脂族及芳族胺,包括L-精氨酸、苄苯乙胺(benethamine)、苄乙二胺(benzathine)、胆碱、二甲胺乙醇、二乙醇胺、二乙胺、二甲胺、二丙胺、二异丙基胺、2-(二乙胺基)-乙醇、乙醇胺、乙胺、乙二胺、异丙胺、N-甲基-葡糖胺、哈胺(hydrabamine)、1H-咪唑、L-赖氨酸、吗啉、4-(2-羟乙基)-吗啉、甲胺、哌啶、哌嗪、丙胺、吡咯烷、1-(2-羟乙基)-吡咯烷、吡啶、奎宁环(quinuclidine)、喹啉、异喹啉、二级胺、三乙醇胺、三甲胺、三乙胺、N-甲基-D-葡糖胺、2-胺基-2-(羟甲基)-1,3-丙二醇、胺丁三醇及诸如此类。
本文所提供的化合物也可以前药形式提供,其为例如式(I)的化合物的官能性衍生物,且可易于活体内转化成母体化合物。前药通常适用,因为在一些情况下,其可能比母体化合物更容易给药。其可例如通过口服可能具有生物可利用性,而母体化合物不能。前药也可在药物组合物中相较于母体化合物具有增强的溶解度。前药可经由各种机制转化成母药,包括酶促方法及代谢水解。
本公开提供了药物组合物,其包含本公开所提供的化合物,例如式(I)化合物(包括其立体异构体或非对映异构体、或其药学上可接受的盐、溶剂合物或前药)作为活性成分,以及一种或多种药学上可接受的载体或赋形剂。
适合的载剂或赋形剂为本领域技术人员所熟知的,且适合的赋形剂的非限制性实例提供于本文中。特定赋形剂是否适合于并入药物组合物或剂型中视本领域中熟知的多种因素而定,包括(但不限于)给药方法。举例而言,诸如片剂之口服剂型可含有不适用于非经肠剂型之赋形剂。特定赋形剂之适合性亦可视剂型中之具体活性成分而定。
本公开的药物组合物包含本公开的化合物(例如,包括其立体异构体或非对映异构体的式(I)化合物、或其药学上可接受的盐、溶剂合物或前药),以及一个或多个药学上可接受的载体或赋形剂,和任选的其他治疗成分或佐剂。该药物组合物包括适合于经口、直肠、局部和肠胃外(包括皮下、肌肉内和静脉内)给药的组合物。这些剂型可以根据本领域技术人员已知的常规方法和技术来制备。
本公开所提供的药物组合物可以单位剂型或多重剂型提供。如本公开所用的单位剂型是指以物理方式分散适合于向人类及动物个体给药的单元,且按照本领域已知的那样单独封装。各单位剂量含有预定量的活性成分,其与所需药物载剂或赋形剂结合足以产生所要的治疗效应。单位剂型的实例包括安瓿、注射器及单独封装的片剂(tablet)及胶囊。举例而言,100mg单位剂量在封装的片剂或胶囊中含有约100mg活性成分。单位剂型可以其部分或倍数给药。多重剂型为多个封装于单一容器中的待以分离的单位剂型形式给药的相同单位剂型。多重剂型的实例包括小瓶、片剂或胶囊瓶,或品脱、加仑瓶。
本公开所提供的药物组合物可一次性或以时间间隔多次给药。应理解,精确剂量及治疗持续时间可随所治疗的患者的年龄、体重及条件而变化,且可使用已知测试协议凭经验确定或藉由自活体内或活体外测试或诊断资料外推来确定。此外,应理解,对于任何特定个体,应根据个体需要及管理调配物或监督调配物给药的个人的专业判断随时间推移而调整具体剂量方案。
本公开所提供的用于口服给药的药物组合物可以用于口服给药的固体、半固体或液体剂型提供。如本公开所用,口服给药也包括颊内、经舌及舌下给药。适合的口服剂型包括但不限于片剂、速溶剂、咀嚼片、胶囊、丸剂、带状物、糖衣锭(troches)、***锭(lozenges)、片剂(pastilles)、扁囊剂、丸粒、药用口嚼片、块状粉末、发泡或非发泡粉末或颗粒、口服喷雾、溶液、乳液、悬浮液、粉片、撒剂、酏剂及糖浆剂。除活性成分以外,医药组合物可含有一或多种医药学上可接受之载剂或赋形剂,包括但不限于黏合剂、填充剂、稀释剂、崩解剂、润湿剂、润滑剂、滑动剂、着色剂、染料迁移抑制剂、甜味剂、调味剂、乳化剂、悬浮剂及分散剂、防腐剂、溶剂、非水性液体、有机酸及二氧化碳来源。
黏合剂或造粒剂赋予锭剂内聚性以确保锭剂在压缩之后保持完整。适合之黏合剂或造粒剂包括但不限于淀粉,诸如玉米淀粉、马铃薯淀粉及预糊化淀粉(例如STARCH1500);明胶;糖,诸如蔗糖、葡萄糖、右旋糖、糖蜜及乳糖;天然及合成胶,诸如***胶、褐藻酸、海藻酸盐、鹿角菜(Irish moss)之提取物、潘沃胶(panwar gum)、哥地胶(ghattigum)、洋车前子(isabgol)果壳之黏液、羧甲基纤维素、甲基纤维素、聚乙烯吡咯啶酮(PVP)、维格姆(Veegum)、松木多醣(larch arabogalactan)、粉末状黄蓍及瓜尔豆胶;纤维素,诸如乙基纤维素、乙酸纤维素、羧甲基纤维素钙、羧甲基纤维素钠、甲基纤维素、羟乙基纤维素(HEC)、羟丙基纤维素(HPC)、羟丙基甲基纤维素(HPMC);微晶纤维素,诸如AVICEL-PH-101、AVICEL-PH-103、AVICEL RC-581、AVICEL-PH-105(FMC Corp.,Marcus Hook,PA);及其混合物。适合之填充剂包括但不限于滑石、碳酸钙、微晶纤维素、粉末状纤维素、葡萄糖结合剂、高岭土、甘露醇、硅酸、山梨醇、淀粉、预糊化淀粉及其混合物。
适合之稀释剂包括但不限于磷酸二钙、硫酸钙、乳糖、山梨醇、蔗糖、肌醇、纤维素、高岭土、甘露醇、氯化钠、无水淀粉及粉末状糖。当以足够量存在时,某些稀释剂,诸如甘露醇、乳糖、山梨醇、蔗糖及肌醇,可赋予一些压缩锭剂可藉由咀嚼而在口中崩解之特性。
适合之崩解剂包括但不限于琼脂;膨润土;纤维素,诸如甲基纤维素及羧甲基纤维素;木材产品;天然海绵;阳离子交换树脂;褐藻酸;胶,诸如瓜尔豆胶及维格姆HV;柑桔渣;交联纤维素,诸如交联羧甲纤维素;交联聚合物,诸如交联普维酮(crospovidone);交联淀粉;碳酸钙;微晶纤维素,诸如羟基乙酸淀粉钠;波拉克林钾(polacrilin potassium);淀粉,诸如玉米淀粉、马铃薯淀粉、木薯淀粉及预糊化淀粉;黏土;对准剂;及其混合物。
适合之润滑剂包括但不限于硬脂酸钙;硬脂酸镁;矿物油;轻质矿物油;甘油;山梨醇;甘露醇;二醇,诸如二十二酸甘油酯及聚乙二醇(PEG);硬脂酸;月桂基硫酸钠;滑石;氢化植物油,包括花生油、棉籽油、葵花油、芝麻油、橄榄油、玉米油及大豆油;硬脂酸锌;油酸乙酯;月桂酸乙酯;琼脂;淀粉;石松;二氧化硅或二氧化硅凝胶;及其混合物。
适合之滑动剂包括但不限于胶态二氧化硅及不含石棉之滑石。适合之着色剂包括但不限于任何经批准、经鉴定、可溶于水之FD&C染料,及悬浮于氧化铝水合物上之不可溶于水之FD&C染料,及其色淀及混合物。色淀为由水可溶染料吸附至重金属之含水氧化物而形成之组合,产生染料之不可溶形式。适合之调味剂包括但不限于自植物(诸如果实)提取之天然调味剂,及产生合意口感之化合物(诸如胡椒薄荷及柳酸甲酯)之合成掺合物。适合之甜味剂包括但不限于蔗糖、乳糖、甘露醇、糖浆剂、甘油及人工甜味剂,诸如糖精及阿斯巴甜糖(aspartame)。适合之乳化剂包括但不限于明胶、***胶、黄蓍、膨润土及界面活性剂,诸如聚氧化乙烯脱水山梨糖醇单油酸酯聚氧化乙烯脱水山梨糖醇单油酸酯80及油酸三乙醇胺。适合之悬浮剂及分散剂包括但不限于羧甲基纤维素钠(sodium carboxymethylcellulose)、果胶、黄蓍、维格姆、***胶、羧甲基纤维素钠(sodium carbomethylcellulose)、羟丙基甲基纤维素及聚乙烯吡咯啶酮。适合之防腐剂包括但不限于甘油、对羟基苯甲酸甲酯及对羟基苯甲酸丙酯、苯甲酸添加剂、苯甲酸钠及醇。适合之润湿剂包括但不限于丙二醇单硬脂酸酯、脱水山梨糖醇单油酸酯、二甘醇单月桂酸酯及聚氧化乙烯月桂基醚。适合之溶剂包括但不限于甘油、山梨醇、乙醇及糖浆。乳液中所用的适合之非水性液体包括但不限于矿物油及棉籽油。适合之有机酸包括但不限于柠檬酸及酒石酸。适合之二氧化碳来源包括但不限于碳酸氢钠及碳酸钠。
本公开所提供之医药组合物可藉由注射、灌注或植入而非经肠(肠胃外)投与,以用于局部或全身投药。如本公开所用,非经肠投药包括静脉内、动脉内、腹膜内、鞘内、心室内、尿道内、胸骨内、颅内、肌内、滑膜内、膀胱内及皮下投药。本公开所提供的用于非经肠投药之医药组合物可以任何适合于非经肠投药之剂型(包括溶液、悬浮液、乳液、胶束、脂质体、微球体、奈米***)及适合于在注射之前溶解或悬浮于液体中之固体形式调配。此类剂型可根据熟习医药科学技术者已知之习知方法来制备。
用于非经肠投药之医药组合物可包括一种或多种医药学上可接受之载剂及赋形剂,包括但不限于水性媒剂、水可混溶性媒剂、非水性媒剂、对抗微生物生长之抗微生物剂或防腐剂、稳定剂、溶解度增强剂、等渗剂、缓冲剂、抗氧化剂、局部麻醉剂、悬浮剂及分散剂、润湿剂或乳化剂、错合剂、钳合剂或螯合剂、低温保护剂、冻干保护剂、增稠剂、pH值调节剂及惰性气体。适合之水性媒剂包括但不限于水、食盐水、生理食盐水或磷酸盐缓冲盐水(PBS)、氯化钠注射液、林格氏注射液(Ringers injection)、等渗右旋糖注射液、无菌水注射液、右旋糖及乳酸林格氏注射液。适合之非水性媒剂包括但不限于植物来源之非挥发性油,蓖麻油、玉米油、棉籽油、橄榄油、花生油、薄荷油、红花油、芝麻油、大豆油、氢化植物油、氢化大豆油及椰子油之中链三酸甘油酯,及棕榈籽油。适合之水可混溶性媒剂包括但不限于乙醇、1,3-丁二醇、液体聚乙二醇(例如聚乙二醇300及聚乙二醇400)、丙二醇、甘油、N-甲基-2-吡咯啶酮、N,N-二甲基乙酰胺及二甲亚砜。
本公开所提供的药物组合物可向皮肤、孔口或黏膜局部给药。如本公开所用,局部给药包括经皮(皮内)、经结膜、角膜内、眼内、经眼、经耳、透皮、经鼻、经***、经尿道、经呼吸道及经直肠给药。本公开所提供的药物组合物可以适合于局部给药的任何剂型调配以获得局部或全身作用,包括乳液、溶液、悬浮液、乳膏、凝胶、水凝胶、软膏、敷粉、敷料、酏剂、洗剂、悬浮液、酊剂、糊剂、发泡体、膜、气雾剂、冲洗剂、喷雾剂、栓剂、绷带及经皮贴片。本公开所提供的药物组合物的局部调配物也可包含脂质体、胶束、微球体、纳米***及其混合物。适用于本公开所提供之局部调配物中的医药学上可接受之载剂及赋形剂包括但不限于水性媒剂、水可混溶性媒剂、非水性媒剂、对抗微生物生长之抗微生物剂或防腐剂、稳定剂、溶解度增强剂、等渗剂、缓冲剂、抗氧化剂、局部麻醉剂、悬浮剂及分散剂、润湿剂或乳化剂、错合剂、钳合剂或螯合剂、穿透增强剂、低温保护剂、冻干保护剂、增稠剂及惰性气体。
本公开还提供所公开的化合物,例如式(I)的化合物(包括立体异构体或其对映异构体、或其药学上可接受的盐、溶剂合物或前药)与一种或多种其他治疗剂(包括但不限于第二种不同的抗HBV剂)的组合。例如,本公开所提俩的化合物可以与一种或多种选自以下的抗HBV剂组合:逆转录酶抑制剂(reverse transcriptase inhibitors)、衣壳抑制剂(capsid inhibitors)、cccDNA形成抑制剂(cccDNA formation inhibitors)、HbsAg释放抑制剂(HbsAg release inhibitors)、靶向B型肝炎基因组的寡聚核苷酸、免疫刺激剂、以及机制不同或未知的药剂。在一个实施例中,本公开的化合物与一种或多种另外的治疗剂组合还可以同时、分开或依序施用。
在一个实施例中,逆转录酶抑制剂包括但不限于恩替卡韦(entecavir),克罗夫定(clevudine),替比夫定(telbivudine),拉米夫定(lamivudine),阿德福韦(adefovir),替诺福韦(tenofovir),阿德福韦酯(adefovir dipovoxil),恩曲他滨(emtricitabine),阿巴卡韦(abaccavir),依维他滨(elvucitabine),更昔洛韦(ganciclovir),洛布卡韦(lobucavir),泛昔洛韦(famciclovir),喷昔洛韦(penciclovir),安多索韦(amdoxovir)及诸如此类。
在一个实施例中,衣壳抑制剂包括但不限于抑制衣壳装配、诱导非衣壳聚合物形成、促进衣壳装配过量或衣壳装配错误、影响衣壳稳定或抑制RNA(例如pgRNA)衣壳化的任何化合物。
在一个实施例中,cccDNA形成抑制剂包括但不限于能直接或间接抑制cccDNA形成和/或稳定性的化合物,例如,cccDNA形成抑制剂可包括但不限于抑制衣壳解体、rcDNA进入细胞核或rcDNA转化为cccDNA的任何化合物。
在一个实施例中,HBsAg释放抑制剂包括但不限于能直接或间接抑制携带亚病毒颗粒的sAg(S、M和/或L表面抗原)和/或含有病毒颗粒的DNA从HBV感染细胞分泌的任何化合物。
在一个实施例中,靶向B型肝炎基因组的寡聚核苷酸包括但不限于分离的双股siRNA分子(其各自包含义股和与该义股杂交的反义股),例如Arrowhead-ARC-520。
在一个实施例中,免疫刺激剂包括但不限于IFN基因刺激剂的激动剂(STING)、白介素、干扰素、TLR-7激动剂(包括但不限于GS-9620、RG-7795)、T细胞刺激剂(包括但不限于GS-4774)、RIG-1抑制剂(包括但不限于SB-9200)或SMAC模拟物(包括但不限于Birinapant)。
本公开还提供了试剂盒(Kit),其包含本公开所提供的化合物,例如式(I)的化合物(包括立体异构体或其对映异构体、或其药学上可接受的盐、溶剂合物或前药),及/或不同剂型的其他活性成分。试剂盒可进一步包含使用说明书,例如用于治疗HBV感染的说明书。使用说明通常是书面说明,但是包含说明的电子存储介质(例如磁盘或光盘)也是可以接受的。
以下说明合成本公开示例化合物的方法。除非另有说明,否则所有试剂和溶剂均购自商业来源并且无需进一步纯化即可使用。所有反应均在干燥氮气或氩气下进行,并使用Merck Silica Gel 60F254玻璃背板通过薄层色谱(TLC)监测。通过Merck Silica Gel 60(0.040-0.063mm,230-400mesh)进行管柱层析。通过Varian Mercury-300和Varian BrukerAVIII-500光谱仪测量1H NMR和13C NMR光谱,化学位移(δ)以每百万分之一(ppm)计且相对于溶剂共振峰。使用以下缩写来表示多重性:s(单重态)、d(双重态)、t(三重态)、q(四重态)、quin(五重态)、m(多重态)或br(宽)。通过HP Hewlett Packard 1100系列来测量低分辨率质谱。
式(I)化合物可依方案1的通用步骤来合成:
方案1
在一实施例中,可以如方案1所示的方法制备式(I)化合物。首先通过与R1-Y反应将化合物I-1转化为化合物I-2。然后化合物I-2与化合物I-3反应形成化合物I-4。随后,化合物I-4与氯磺酸三甲基甲硅烷基酯反应形成化合物I-5,然后将其用SOCl2处理以形成化合物I-6。通过与化合物I-7反应将化合物I-6转化为化合物I-8。使化合物I-8脱保护,然后与化合物I-9反应以获得化合物I-10。
对于方案1中所示的化合物,其中,Ra、Rb、Rc、Rd、R1、R2、R3、R4和R5如本公开所述的任何实施例所定义。PG是氨基保护基。
通过以下非限制性实施例将进一步理解本公开。
实施例1:化合物1至100的制备及表征
对于所有以下实例,可使用本领域技术人员已知的标准处理及纯化方法。除非另外指示,否则所有温度均以℃(摄氏度)表示。除非另外指出,否则所有反应均在室温下进行。本文中的合成方法意欲经由使用具体实例来例示可适用的化学方法且不指示本发明的范畴。
在本公开所描述的实例中使用的起始材料为市售可得的或可通过本领域技术人员已知的方法来制备。
化合物1的合成与表征
化合物1(1-(1-氟-5,11-二氢-10-硫杂-二苯并[a,d]环庚烯-5-基)-5-羟基-3,3-环丙基-2,3-二氢-1H-吡啶并[1,2-b]吡嗪-4,6-二酮)的合成。
化合物1-ii首先按照以下所示方案先由市售3-氟-1H-吡咯-2-羧酸乙酯(3-Fluoro-1H-pyrrole-2-carboxylic acid ethyl carboxy)再经由中间体1-i进行制备:
在0℃下,向3-氟-1H-吡咯-2-羧酸乙酯(30g;191mmol)在无水DMF(600mL)中的溶液中加入氢化钠(NaH,9.16mg,229mmol,在矿物油中的60%),将混合物搅拌30分钟,然后在冰浴上逐滴(约15分钟)加入碘甲烷(30mL;482mmol),将反应混合物温热至室温并搅拌16小时。将反应混合物用1N盐酸(水溶液)酸化并浓缩。将残余物溶解在水/乙酸乙酯(EtOAc)中。有机层经硫酸镁(MgSO4)干燥、过滤并浓缩。将获得的粗化合物1-i溶解于THF/MeOH(200/150mL)中,并在室温下加入2N氢氧化钠(水溶液)(350mL;4.0当量),将混合物加热至50℃保持3小时。待水解完成后,蒸发以除去溶剂,并将水层用浓盐酸(pH=2~3)酸化,过滤并收集沉淀物,接着真空干燥,得到化合物1-ii,为灰白色固体(27.2g,分两步收率=99.5%)。
在室温下向化合物1-ii(9g,62.9mmol)的无水DMF(300mL)溶液中加入HATU(35.9g,94.4mmol),将混合物搅拌15分钟。然后依次加入3,4-二氟苯胺(3,4-Difluoroaniline,12.2g,94.5mmol)和N,N-二异丙基乙胺(N,N-Diisopropylethylamine,54.8mL,314.6mmol),将反应混合物加热至70℃直至通过LC-MS检查反应完成。然后将混合物用乙酸乙酯稀释,依次用1N盐酸(水溶液)、水和盐水洗涤。有机层经硫酸镁干燥、过滤并浓缩。将获得的残余物通过硅胶柱色谱法纯化,用乙酸乙酯/己烷(1:9)洗脱,得到化合物1-iii,为灰白色固体(12.0g,产率=75%)。
在0℃下,向化合物1-iii(6.0g,23.6mmol)的无水二氯甲烷(CH2Cl2,240mL)溶液中加入氯磺酸三甲基甲硅烷基酯(Trimethylsilyl chlorosulfonate,6.6g,35.0mmol),将混合物在冰水浴中搅拌1小时,得到浅黄色固体形式的化合物1-iv,将其悬浮在二氯甲烷中。反应完成后,将氯化亚砜(SOCl2,17.0mL,234mmol)和干燥的DMF(3.6mL,46.5mmol)加入上述溶液中,保持溶液澄清并加热至40℃2小时。浓缩反应混合物,并将获得的深黄色油状物经硅胶管柱色谱纯化,使用乙酸乙酯作为洗脱剂,将产物级分浓缩并在二氯甲烷/己烷中重结晶,得到化合物1-v,为灰白色固体(6.0g,分两步收率=72%)。
经由中间体1-v至1-vii如下制备化合物1。在冰水浴中加入化合物1-v(1.5g,4.3mmol)在二氯甲烷(20mL)中的溶液(R)-3-氨基-N-Boc-吡咯烷((R)-3-Amino-N-Boc-pyrrolidine;1.0g,5.4mmol)和N,N-二异丙基乙胺(1.5mL,8.6mmol),将反应混合物温热至室温并搅拌16小时。用1N盐酸(水溶液)淬灭反应,用水和盐水洗涤混合物。有机层经硫酸镁干燥、过滤并浓缩。将获得的残余物通过硅胶管柱色谱法纯化,使用在己烷中的10至50%乙酸乙酯的梯度,得到化合物1-vi,为灰白色固体(2.1g,收率=97%)。
将化合物1-vi(2.1g,4.2mmol)溶于二氯甲烷/甲醇(1:1,20mL)中,加入4N盐酸/1,4-二恶烷(5.4mL,21.6mmol),并将混合物在室温下搅拌3小时,接着蒸发,得到脱保护的化合物1-vii,为浅黄色盐酸盐(定量收率)。
在冰水浴中向化合物1-vii(100mg,0.23mmol)的二氯甲烷(5mL)溶液中加入NEt3(0.16mL,1.15mmol),然后逐滴加入环丙烷磺酰氯(Cyclopropanesulfonyl chloride;50mg,0.36mmol)。将反应混合物在0℃搅拌1小时,并用1N盐酸(水溶液)进行淬灭反应,用水和盐水洗涤混合物。有机层经硫酸镁干燥、过滤并浓缩。所得残余物通过管柱色谱法纯化(乙酸乙酯/己烷=3/7作为洗脱剂),并将产物级分浓缩并在二氯甲烷/己烷中重结晶,得到化合物1,为灰白色固体(90mg,产率=77%)。MS:m/z 507.0(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.30(s,1H),8.10(s,1H),7.86-7.78(m,1H),7.54(d,1H),7.43-7.40(m,2H),3.80(s,3H),3.78-3.76(m,1H),3.48-3.39(m,1H),3.36-3.25(m,3H),3.19-3.14(m,1H),2.71-2.63(m,1H),2.10-2.02(m,1H),1.90-1.81(m,1H),0.99-0.91(m,4H)。
依照前述方案1以及制备化合物1中所描述的相似方法来制备化合物2至化合物100。化合物2至100的光谱分析数据如下所列:
化合物2:MS:m/z 521.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.29(s,1H),8.11(d,1H),7.85-7.78(m,1H),7.53(d,1H),7.45-7.40(m,2H),3.80(s,3H),3.79-3.77(m,1H),3.48-3.41(m,2H),3.33(s,3H),3.21-3.16(m,2H),2.11-2.02(m,1H),1.91-1.82(m,1H),1.13-1.09(m,2H),0.83-0.79(m,2H)。
化合物3:MS:m/z 535.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.29(s,1H),8.08(s,1H),7.85-7.78(m,1H),7.53(d,1H),7.45-7.40(m,2H),3.80(s,3H),3.78-3.74(m,1H),3.72-3.61(m,1H),3.47-3.41(m,1H),3.37-3.24(m,2H),3.19-3.13(m,1H),2.10-2.01(m,2H),1.99-1.90(m,2H),1.88-1.70(m,2H),1.67-1.58(m,2H),1.57-1.49(m,2H)。
化合物4:MS:m/z 525.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.29(s,1H),8.07(s,1H),7.85-7.78(m,1H),7.53(d,1H),7.45-7.40(m,2H),3.80(s,3H),3.77-3.71(m,1H),3.66-3.62(m,2H),3.46-3.41(m,1H),3.38-3.28(m,4H),3.25(s,3H),3.14-3.07(m,1H),2.06-2.00(m,1H),1.86-1.79(m,1H)。
化合物5:MS:m/z 496.0(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.24(s,1H),8.04(d,1H),7.82-7.74(m,1H),7.48(d,1H),7.41-7.36(m,2H),6.99(dd,1H),3.76-3.70(m,4H),3.34-3.29(m,1H),3.26-3.15(m,1H),3.12-3.07(m,1H),3.01-2.96(m,1H),2.47(s,3H),2.06-1.99(m,1H),1.80-1.70(m,1H)。
化合物6:MS:m/z 514.0(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.36(s,1H),8.09(d,1H),7.62-7.52(m,3H),7.02(dd,1H),3.78-3.72(m,4H),3.35-3.31(m,1H),3.27-3.19(m,1H),3.16-3.08(m,1H),3.02-2.97(m,1H),2.48(s,3H),2.09-1.99(m,1H),1.83-1.74(m,1H)。
化合物7:MS:m/z 503.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.37(s,1H),8.15(dd,1H),8.09(d,1H),7.96-7.90(m,1H),7.55-7.49(m,2H),7.02(dd,1H),3.79-3.72(m,4H),3.36-3.31(m,1H),3.27-3.19(m,1H),3.16-3.08(m,1H),3.02-2.97(m,1H),2.48(s,3H),2.09-1.99(m,1H),1.83-1.74(m,1H)。
化合物8:MS:m/z 576.0(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.44(s,1H),8.32(d,1H),7.82-7.75(m,1H),7.45-7.38(m,2H),7.02(dd,1H),3.82-3.77(m,4H),3.37-3.20(m,2H),3.19-3.07(m,1H),3.01-2.96(m,1H),2.46(s,3H),2.07-2.00(m,1H),1.84-1.74(m,1H)。
化合物9:MS:m/z 510.0(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.29(s,1H),8.10(s,1H),7.85-7.78(m,1H),7.53(d,1H),7.45-7.40(m,2H),3.80(s,3H),3.77-3.73(m,1H),3.40-3.31(m,2H),3.28-3.18(m,1H),3.13-3.08(m,1H),2.72(s,6H),2.11-2.00(m,1H),1.88-1.79(m,1H)。
化合物10:MS:m/z 522.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 9.88(s,1H),8.02(d,1H),7.83-7.76(m,1H),7.43-7.38(m,2H),7.06-7.02(m,1H),4.26-4.22(m,2H),3.78-3.74(m,1H),3.37-2.98(m,6H),2.71(s,3H),2.49-2.34(m,2H),2.06-1.97(m,1H),1.81-1.74(m,1H)。
化合物11:MS:m/z 536.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.14(s,1H),7.93(d,1H),7.81-7.74(m,1H),7.40-7.35(m,2H),7.04-6.99(m,1H),4.10(t,2H),3.72-3.68(m,1H),3.28-3.06(m,3H),2.99-2.94(m,1H),2.89-2.85(m,2H),2.46(d,3H),2.05-1.95(m,1H),1.86-1.81(m,2H),1.78-1.69(m,3H)。
化合物12:MS:m/z 556.0(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.16(s,1H),7.97(d,1H),7.66-7.58(m,2H),7.05-7.00(m,1H),4.25-4.20(m,2H),3.76-3.70(m,1H),3.29-3.20(m,2H),3.15-3.00(m,4H),2.43(s,3H),2.41-2.36(m,2H),2.05-1.95(m,1H),1.83-1.74(m,1H)。
化合物13:MS:m/z 561.0(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.27(s,1H),7.87-7.76(m,4H),7.49-7.34(m,5H),5.72(s,3H),3.51-3.46(m,1H),3.33-3.26(m,1H),3.23-3.14(m,1H),3.03-2.94(m,1H),2.88-2.78(m,1H),1.76-1.67(m,1H),1.44-1.36(m,1H)。
化合物14:MS:m/z 569.0(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.27(s,1H),8.06(d,1H),7.85-7.80(m,1H),7.78-7.72(m,2H),7.49(d,1H),7.44-7.38(m,3H),7.34(s,1H),7.29(s,1H),3.76(s,3H),3.74-3.72(m,1H),3.45-3.39(m,1H),3.37-3.31(m,2H),3.29-3.22(m,2H),3.20-3.12(m,1H),2.04-1.96(m,1H),1.86-1.77(m,1H)。
化合物15:MS:m/z 530.0(M+1);1H NMR(300MHz,DMSO-d6)δppm 9.88(s,1H),8.09(d,1H),7.67-7.59(m,1H),7.53(d,1H),7.34(t,1H),7.03(dd,1H),3.79-3.72(m,4H),3.36-3.20(m,2H),3.17-3.11(m,1H),3.03-2.98(m,1H),2.47(s,3H),2.10-1.97(m,1H),1.84-1.75(m,1H)。
化合物16:MS:m/z 528.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.27(s,1H),8.05(d,1H),8.00-7.97(m,1H),7.79-7.76(m,1H),7.49(d,1H),7.38-6.98(m,3H),3.77-3.71(m,4H),3.36-3.20(m,2H),3.18-3.07(m,1H),3.02-2.96(m,1H),2.47(s,3H),2.06-1.98(m,1H),1.83-1.74(m,1H)。
化合物17:MS:m/z 541.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.33(s,1H),8.07(d,1H),7.84-7.76(m,1H),7.56(d,1H),7.43-7.38(m,2H),7.02(dd,1H),4.22(dd,2H),3.76(dd,1H),3.35-3.08(m,3H),3.01-2.96(m,1H),2.47(s,3H),2.07-1.98(m,1H),1.83-1.74(m,1H)7.27(t,3H)。
化合物18:MS:m/z 517.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 9.99(s,1H),7.96(d,1H),7.56(dd,1H),7.48-7.42(m,2H),7.09(t,1H),3.77(s,3H),3.59(dd,1H),3.42(d,1H),3.16-3.14(m,1H),2.76-2.47(m,3H),2.21(s,3H),1.74-1.72(m,2H),1.46-1.26(m,2H),0.97-0.79(m,4H)。
化合物19:MS:m/z 524.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.13(s,1H),7.84-7.76(m,1H),7.69(d,1H),7.45-7.38(m,3H),7.12-7.07(m,1H),3.85(s,3H),3.32-3.24(m,3H),2.76-2.25(m,5H),1.72-1.39(m,3H),0.94-0.72(m,3H)。
化合物20:MS:m/z 524.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.22(s,1H),7.83-7.56(m,1H),7.55(s,1H),7.48(d,1H),7.42-7.40(m,2H),7.09-7.07(m,1H),3.77(s,3H),3.32-3.17(m,2H),2.84(d,1H),2.71-2.64(m,1H),2.45(s,3H),1.69-1.30(m,4H),0.86(s,3H)。
化合物21:MS:m/z 542.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.34(s,1H),8.15(s,1H),7.96(d,1H),7.89(d,1H),7.59(dd,1H),7.52(d,1H),7.46(d,1H),7.13(dd,1H),3.80(s,3H),3.49(dd,1H),3.30-3.27(m,1H),3.24-3.08(m,1H),2.62-2.56(m,1H),2.49(d,3H),2.42(d,1H),1.73-1.69(m,2H),1.48-1.37(m,1H),1.32-1.21(m,1H)。
化合物22:MS:m/z 524.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.30(s,1H),7.94(d,1H),7.86-7.78(m,1H),7.57(d,1H),7.45-7.40(m,2H),7.12(d,1H),4.23(q,2H),3.49(dd,1H),3.33-3.29(m,1H),3.24-3.07(m,1H),2.59-2.56(m,1H),2.49(d,3H),2.46(d,1H),1.74-1.70(m,2H),1.46-1.32(m,2H),1.28(t,3H)。
化合物23:MS:m/z 538.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.23(s,1H),7.83-7.76(m,2H),7.42(d,1H),7.43-7.38(m,2H),7.08(d,1H),3.78(s,3H),3.38-3.15(m,3H),2.71-2.64(m,3H),1.78-1.75(m,2H),1.51-1.41(m,2H),1.07(s,3H),1.5(s,3H)。
化合物24:MS:m/z 535.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.24(s,1H),7.89-7.76(m,2H),7.70-7.38(m,3H),3.78(s,3H),3.56-3.51(m,2H),3.27-3.23(m,1H),3.03-2.96(m,2H),1.78-1.74(m,2H),1.48-1.40(m,2H),1.35(s,3H),1.12-1.08(m,1H),0.79-0.75(m,1H)。
化合物25:MS:m/z 524.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.21(s,1H),7.83-7.76(m,1H),7.48-7.38(m,4H),7.03-7.00(m,1H),3.77(s,3H),3.10-2.94(m,4H),2.48(s,3H),1.98-1.94(m,2H),1.51-1.43(m,2H),1.17(m,3H)。
化合物26:MS:m/z 521.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.24(s,1H),8.26(s,1H),7.85-7.78(m,1H),7.52(d,1H),7.45-7.40(m,2H),3.80(s,3H),3.04-2.97(m,4H),2.91-2.84(m,1H),2.08-1.93(m,2H),1.35-1.29(m,2H),1.16(t,3H),1.01-0.98(m,1H),0.59-0.55(m,1H)。
化合物27:MS:m/z 546.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.23(s,1H),8.31(d,1H),7.82-7.75(m,1H),7.44-7.33(m,3H),7.25(dd,1H),3.75-3.61(m,4H),3.58-3.42(m,1H),3.34(d,1H),3.29-3.15(m,1H),2.97-2.90(m,1H),2.45(d,3H),1.73-1.64(m,2H)。
化合物28:MS:m/z 581.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.13(s,1H),7.77(d,1H),7.66-7.59(m,2H),4.26-4.21(m,2H),3.50-3.43(m,2H),3.22-3.19(m,1H),3.05-3.00(m,2H),2.94-2.87(m,2H),2.42-2.39(m,3H),1.77-1.74(m,2H),1.55-1.44(m,2H),0.99-0.88(m,4H)。
化合物29:MS:m/z 524.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.20(s,1H),7.83-7.74(m,2H),7.45-7.38(m,3H),6.88(d,1H),6.58(dd,1H),3.76(s,3H),3.02-2.98(m,1H),2.87-2.84(m,1H),2.35(d,3H),1.97(d,1H),1.77(d,1H),1.61(t,2H),1.21-0.94(m,4H)。
化合物30:MS:m/z 520.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.35(s,1H),8.10(S,1H),7.63-7.51(m,3H),3.82-3.68(m,4H),3.46-3.33(m,2H),3.30-3.15(m,2H),2.85-2.80(m,6H),2.05-2.02(m,1H),1.88-1.77(m,1H)。
化合物31:MS:m/z 538.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.24(d,1H),8.93(t,1H),8.03(s,1H),7.76(dd,1H),7.47(t,1H),7.43-7.32(m,2H),6.20-5.78(m,1H),3.80-3.66(m,5H),3.64-3.54(m,1H),3.51-3.40(m,3H),3.39-3.30(m,1H),2.03-1.73(m,2H)。
化合物32:MS:m/z 532.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.25(d,1H),8.55(t,1H),8.03(s,1H),7.78(dd,1H),7.50-7.42(m,1H),7.41-7.33(m,2H),3.81-3.71(m,5H),3.69-3.59(m,1H),3.57-3.41(m,1H),3.38-3.24(m,3H),3.23-3.16(m,5H),2.04-1.72(m,2H)。
化合物33:MS:m/z 514.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.21(s,1H),8.60(s,1H),8.01(s,1H),7.76(dd,1H),7.48(d,1H),7.40-7.33(m,2H),3.77-3.70(m,5H),3.68-3.55(m,1H),3.50-3.38(m,1H),3.35-3.21(m,1H),2.70-2.63(m,1H),2.04-1.74(m,2H),0.65-0.50(m,4H)。
化合物34:MS:m/z 512.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.24(d,1H),9.02(t,1H),8.04(d,1H),7.78(dd,1H),7.49(t,1H),7.45-7.34(m,2H),3.86-3.83(m,2H),3.77-3.69(m,5H),3.67-3.59(m,1H),3.53-3.40(m,1H),3.38-3.27(m,1H),3.08-3.05(m,1H),2.05-1.76(m,2H)。
化合物35:MS:m/z 536.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 11.75(d,1H),10.32(d,1H),8.06(d,1H),7.61-7.50(m,3H),3.84-3.61(m,7H),3.59-3.48(m,1H),3.46-3.39(m,1H),3.35-3.22(m,1H),2.04-1.77(m,2H),1.10(dd,3H)。
化合物36:MS:m/z 548.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.32(s,1H),9.36(d,1H),8.03(s,1H),7.60-7.49(m,3H),4.83-4.74(m,1H),4.66-4.60(m,2H),4.52-4.48(m,2H),3.77-3.65(m,5H),3.63-3.53(m,1H),3.51-3.43(m,1H),3.41-3.29(m,1H),2.04-1.77(m,2H)。
化合物37:MS:m/z 536.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.32(s,1H),8.46(t,1H),8.04(s,1H),7.63-7.50(m,3H),4.67(t,1H),3.85-3.59(m,6H),3.52-3.29(m,4H),3.17-3.10(m,2H),2.04-1.73(m,2H)。
化合物38:MS:m/z 600.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.34(d,1H),8.72(t,1H),8.06(d,1H),7.60-7.50(m,3H),4.00(d,2H),3.80-3.68(m,5H),3.66-3.46(m,1H),3.42-3.67(m,1H),3.30-3.24(m,3H),2.05-1.77(m,5H)。
化合物39:MS:m/z 588.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.32(d,1H),9.18(dd,1H),8.08(s,1H),7.60-7.50(m,3H),4.60-4.50(m,1H),3.77-3.59(m,5H),3.57-3.41(m,2H),3.38-3.22(m,1H),2.05-1.76(m,2H),1.25(t,3H)。
化合物40:MS:m/z 520.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.27(d,1H),8.55-8.54(m,1H),8.03-7.97(m,2H),7.79-7.76(m,1H),7.49(t,1H),7.38-7.02(m,2H),3.83-3.52(m,6H),3.50-3.40(m,1H),3.37-3.24(m,1H),2.60-2.53(m,3H),2.05-1.73(m,2H)。
化合物41:MS:m/z 504.0(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.22(d,1H),8.54(s,1H),8.03(s,1H),7.93(dd,1H),7.60-7.54(m,1H),7.49(t,1H),7.38(t,1H),3.83-3.59(m,6H),3.52-3.42(m,1H),3.40-3.27(m,1H),2.61-2.58(m,3H),2.02-1.76(m,2H)。
化合物42:MS:m/z 511.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.66(s,1H),8.65(s,1H),8.56(d,1H),8.18-8.16(m,1H),7.99-7.95(m,1H),7.66(d,1H),7.54(t,1H),3.83-3.63(m,4H),3.51-3.43(m,1H),2.64-2.60(m,6H),1.98-1.79(m,2H)。
化合物43:MS:m/z 540.0(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.50(d,1H),8.55(t,1H),8.37(s,1H),7.58(dd,2H),3.82-3.75(m,5H),3.70-3.63(m,1H),3.52-3.41(m,1H),3.37-3.30(m,1H),2.61-2.59(m,3H),2.03-1.77(m,2H)。
化合物44:MS:m/z 502.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.31-10.18(m,1H),8.63-8.50(m,1H),7.98-7.77(m,2H),7.48-7.33(m,2H),3.84-3.72(m,2H),3.69(s,3H),3.66-3.59(m,2H),3.48-3.41(m,1H),3.27(s,3H),2.59-2.55(m,3H),2.07-1.80(m,2H)。
化合物45:MS:m/z 546.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 9.98(s,1H),8.64(t,1H),8.03(s,1H),7.65-7.59(m,2H),4.25(t,2H),3.82-3.59(m,4H),3.51-3.39(m,1H),3.14-3.10(m,2H),3.07-2.97(m,2H),2.43-2.36(m,2H),2.04-1.82(m,2H),1.05-0.98(dd,3H)。
化合物46:MS:m/z 546.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.20(d,1H),8.54(d,1H),7.91(s,1H),7.60-7.54(m,2H),4.09(t,2H),3.78-3.60(m,3H),3.58-3.41(m,1H),2.87-2.70(m,2H),2.61-2.58(m,3H),2.05-1.92(m,1H),1.87-1.83(m,3H),1.81-1.74(m,3H)。
化合物47:MS:m/z 548.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.15(s,1H),8.57(t,1H),7.95(s,1H),7.65-7.60(m,2H),4.23(t,2H),3.82-3.63(m,3H),3.50-3.30(m,2H),3.04-3.00(m,2H),2.66-2.61(m,3H),2.44-2.37(m,2H),2.00-1.78(m,2H)。
化合物48:MS:m/z 538.0(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.44(s,1H),8.56(s,1H),8.18(s,1H),7.81-7.75(m,1H),7.58(s,1H),7.46-7.38(m,2H),6.36(t,1H),4.75(t,2H),3.82-3.70(m,2H),3.68-3.61(m,1H),3.53-3.41(m,1H),3.37-3.29(m,1H),2.60(s,3H),2.03-1.89(m,1H),1.87-1.74(m,1H)。
化合物49:MS:m/z 514.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.42(s,1H),8.56(d,1H),8.03(s,1H),7.85-7.79(m,1H),7.44-7.39(m,3H),3.83-3.70(m,3H),3.67-3.57(m,1H),3.51-3.40(m,1H),3.37-3.25(m,1H),2.61(s,3H),2.02-1.91(m,1H),1.86-1.73(m,1H),0.92-0.81(m,4H)。
化合物50:MS:m/z 528.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.39(s,1H),8.55(s,1H),8.06(s,1H),7.83-7.76(m,1H),7.58(s,1H),7.43-7.40(m,2H),4.06(d,2H),3.83-3.70(m,3H),3.68-3.61(m,1H),3.53-3.41(m,1H),3.38-3.27(m,1H),2.60(s,3H),2.03-1.90(m,1H),1.87-1.74(m,1H),0.93-0.79(m,2H),0.49-0.32(m,2H)。
化合物51:MS:m/z 516.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.34(s,1H),8.57(s,1H),8.03(s,1H),7.83-7.75(m,1H),7.55(s,1H),7.46-7.38(m,2H),4.17(t,2H),3.81-3.70(m,2H),3.68-3.60(m,1H),3.52-3.43(m,1H),3.40-3.26(m,1H),2.60(s,3H),2.02-1.93(m,1H),1.89-1.78(m,1H),1.69-1.57(m,2H),0.76(t,3H)。
化合物52:MS:m/z 514.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.35(s,1H),8.57(d,1H),8.08(s,1H),7.81-7.74(m,1H),7.53(d,1H),7.42-7.37(m,2H),5.98-5.89(m,1H),5.13(d,1H),4.96(d,1H),4.85(d,2H),3.82-3.70(m,2H),3.64-3.60(m,1H),3.50-3.43(m,1H),3.32-3.25(m,1H),2.60(s,3H),2.00-1.94(m,1H),1.85-1.78(m,1H)。
化合物53:MS:m/z 542.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.50(s,1H),8.57(d,1H),8.03(s,1H),7.82-7.76(m,1H),7.50(t,1H),7.43-7.38(m,2H),5.04-4.98(m,1H),3.81-3.70(m,2H),3.64-3.58(m,1H),3.52-3.40(m,1H),3.33-3.29(m,1H),2.60(s,3H),2.08-1.94(m,3H),1.81-1.73(m,3H),1.62-1.57(m,2H),1.26-1.20(m,2H)。
化合物54:MS:m/z 534.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.34(s,1H),8.59(dd,1H),8.05(s,1H),7.64-7.58(m,2H),7.52(dd,1H),3.80(s,3H),3.77-3.74(m,1H),3.67-3.62(m,1H),3.51-3.40(m,1H),3.37-3.26(m,2H),3.10(q,2H),2.36-2.26(m,1H),1.02(t,3H),0.90(d,3H)。
化合物55:MS:m/z 518.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.29(d,1H),8.51-8.50(m,2H),7.61-7.53(m,3H),4.02-3.53(m,6H),3.38-3.19(m,1H),2.59-2.54(m,3H),1.69-1.60(m,1H),0.95-0.92(m,1H),0.54-0.49(m,1H)。
化合物56:MS:m/z 506.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.35(s,1H),8.67(t,1H),8.46(s,1H),7.60-7.51(m,3H),4.65-4.59(m,1H),4.23-4.11(m,3H),3.77(s,3H),3.73-3.68(m,1H),3.09-3.00(m,2H),0.97(t,3H)。
化合物57:MS:m/z 536.0(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.65(d,1H),8.56-8.50(m,1H),7.87(s,1H),7.66-7.59(m,3H),4.18-3.94(m,1H),3.78(s,3H),3.70-3.52(m,1H),2.99-2.86(m,1H),2.73-2.60(m,4H),1.84-1.80(m,1H),1.69-1.66(m,1H),1.46-1.24(m,3H)。
化合物58:MS:m/z 502.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.31(s,1H),8.05(d,1H),7.93(s,1H),7.86-7.79(m,1H),7.65(d,1H),7.55(d,1H),7.49-7.37(m,2H),4.23(q,2H),4.14(dd,1H),3.96(d,1H),3.78(dd,1H),3.53(d,1H),3.19-3.08(m,1H),3.01-2.86(m,1H),2.73-2.56(m,1H),1.84-1.78(m,1H),1.70-1.66(m,1H),1.29(t,3H)。
化合物59:MS:m/z 532.0(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.31(s,1H),8.54(s,1H),8.35(d,1H),7.62-7.51(m,3H),4.17(d,1H),3.62(s,3H),3.60(d,1H),3.06-2.98(m,1H),2.79-2.70(m,1H),2.61(s,3H),1.96-1.94(m,1H),1.59-1.49(m,1H),1.24(d,1H),0.93-0.82(m,1H),0.55-0.42(m,1H)。
化合物60:MS:m/z 514.0(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.30(s,1H),7.60-7.55(m,3H),7.17(d,1H),6.78(dd,1H),3.79(s,3H),3.63(dd,1H),3.40-3.23(m,2H),3.18-3.10(m,1H),3.03-2.98(m,1H),2.39(d,3H),2.06-2.00(m,1H),1.75-1.69(m,1H)。
化合物61:MS:m/z 520.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.23(s,1H),8.81(d,1H),8.72(t,1H),7.61-7.55(m,3H),4.15(dd,1H),3.78(s,3H),3.39-3.30(m,2H),3.23-3.02(m,4H),2.05-1.91(m,2H),0.97(t,3H)。
化合物62:MS:m/z 550.0(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.30(s,1H),7.61-7.54(m,3H),6.98(d,1H),6.57(dd,1H),3.79(s,3H),3.39-3.35(m,2H),3.03-3.01(m,1H),2.61-2.54(m,2H),2.38(d,3H),1.88(d,2H),1.50(dd,2H)。
化合物63:MS:m/z 534.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.23(s,1H),8.76-8.71(m,2H),7.60-7.53(m,3H),3.78(s,3H),3.63-3.50(m,3H),3.15-3.06(m,2H),2.51-2.40(m,2H),1.71-1.61(m,4H),1.00(t,3H)。
化合物64:MS:m/z 534.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.34(s,1H),8.80(t,1H),8.59(d,1H),7.61-7.53(m,3H),3.79-3.78(m,4H),3.41-3.30(m,2H),3.16-3.07(m,2H),2.34(t,2H),1.79-1.66(m,2H),1.57-1.36(m,2H),1.01(t,3H)。
化合物65:MS:m/z 520.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.35(s,1H),8.62(t,1H),7.59-7.54(m,3H),3.79(s,3H),3.58-3.55(m,4H),3.13-3.04(m,2H),2.97-2.46(m,4H),0.99(t,3H)。
化合物66:MS:m/z 514.0(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.34(s,1H),7.60-7.54(m,3H),7.22(dd,1H),3.79(s,3H),3.16-3.14(m,4H),3.03-3.01(m,4H),2.48-2.47(s,3H)。
化合物67:MS:m/z 507.0(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.30(s,1H),7.86-7.78(m,1H),7.63(d,1H),7.46-7.41(m,2H),4.41(q,2H),3.81(s,3H),3.40-3.24(m,2H),3.19-3.05(m,2H),2.56-2.43(m,2H),1.74-1.70(m,1H),1.38-1.34(m,1H),1.17(t,3H)。
化合物68:MS:m/z 506.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.32(s,1H),8.03(s,1H),7.91(d,1H),7.61-7.56(m,3H),7.48(d,1H),4.00(d,1H),3.77(s,3H),3.64(d,1H),3.31-3.30(m,1H),3.09(t,1H),2.83(t,1H),1.76-1.73(m,2H),1.40-1.29(m,2H)。
化合物69:MS:m/z 534.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.33(s,1H),8.62(t,1H),7.91(d,1H),7.61-7.56(m,2H),7.49(d,1H),4.01(d,1H),3.77(s,3H),3.64(d,1H),3.32-3.30(m,1H),3.14-3.05(m,3H),2.84(t,1H),1.76-1.71(m,2H),1.39-1.30(m,2H),1.00(t,3H)。
化合物70:MS:m/z 532.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.33(s,1H),8.61(t,1H),7.90(d,1H),7.60(d,1H),7.54-7.47(m,2H),7.14(dd,1H),4.01(d,1H),3.77(s,3H),3.63(d,1H),3.13-3.04(m,3H),2.84(t,1H),1.76-1.71(m,2H),1.42-1.20(m,3H),1.00(t,3H)。
化合物71:MS:m/z 512.2(M+1);1H NMR(300MHz,DMSO-d6)δppm 9.98(s,1H),8.61(t,1H),7.85(d,1H),7.57-7.53(m,1H),7.46-7.41(m,2H),7.08(t,1H),4.01(d,1H),3.75(s,3H),3.63(d,1H),3.33-3.23(m,1H),3.13-3.04(m,3H),2.84(t,1H),2.18(d,3H),1.76-1.72(m,2H),1.39-1.29(m,2H),0.99(t,3H)。
化合物72:MS:m/z 514.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.19(s,1H),8.61(t,1H),7.87(d,1H),7.82-7.81(m,1H),7.54(d,1H),7.50(d,1H),7.34(t,1H),7.13(dd,1H),4.00(d,1H),3.76(s,3H),3.63(d,1H),3.29-3.23(m,1H),3.12-3.03(m,3H),2.83(t,1H),1.75-1.71(m,2H),1.42-1.21(m,2H),0.99(t,3H)。
化合物73:MS:m/z 548.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.33(s,1H),8.61(t,1H),8.11(s,1H),7.90-7.84(m,2H),7.55(t,1H),7.47-7.41(m,2H),4.00(d,1H),3.77(s,3H),3.63(d,1H),3.30-3.29(m,1H),3.13-3.06(m,3H),2.84(t,1H),1.76-1.72(m,2H),1.39-1.21(m,2H),0.99(t,3H)。
化合物74:MS:m/z 550.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 9.84(s,1H),8.62(t,1H),7.91(d,1H),7.66-7.58(m,1H),7.48(d,1H),7.32(t,1H),4.01(d,1H),3.77(s,3H),3.63(d,1H),3.31-3.30(m,1H),3.13-3.04(m,3H),2.84(t,1H),1.76-1.72(m,2H),1.39-1.30(m,2H),1.00(t,3H)。
化合物75:MS:m/z 562.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.34(s,1H),8.47(d,1H),7.92(d,1H),7.62-7.52(m,2H),7.49(d,1H),4.04-3.98(m,1H),3.78(s,3H),3.73-3.63(m,1H),3.59(d,1H),3.33-3.31(m,1H),3.08(t,1H),2.85(dd,1H),1.75(d,2H),1.44-1.23(m,4H),0.94(t,3H),0.79(t,3H)。
化合物76:MS:m/z 550.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.66(s,1H),8.64(t,1H),7.85(d,1H),7.65-7.59(m,3H),4.04(d,1H),3.77(s,3H),3.67(d,1H),3.16-2.98(m,3H),2.85(t,1H),1.77-1.73(m,2H),1.47-1.23(m,3H),1.03(t,3H)。
化合物77:MS:m/z 572.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 9.94(s,1H),8.72(d,1H),7.87-7.85(d,1H),7.65-7.59(m,2H),4.25(t,2H),4.01(d,1H),3.61(d,1H),3.37-3.20(m,1H),3.14-2.97(m,3H),2.90-2.83(m,1H),2.71-2.65(m,1H),2.43-2.38(m,2H),1.76-1.71(m,2H),1.39-1.30(m,2H),0.67-0.61(m,2H),0.47-0.44(m,2H)。
化合物78:MS:m/z 576.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.13(s,1H),8.64(t,1H),7.78(d,1H),7.66-7.60(m,2H),4.23(t,2H),4.03(d,1H),3.65(d,1H),3.33-3.26(m,1H),3.16-3.00(m,5H),2.90-2.83(m,1H),2.47-2.39(m,2H),1.75-1.68(m,2H),1.41-1.24(m,2H),1.03(t,3H)。
化合物79:MS:m/z 556.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 9.99(s,1H),8.62(t,1H),7.57-7.45(m,3H),4.10(t,2H),3.99(d,1H),3.62(d,1H),3.18-2.98(m,4H),2.95-2.89(m,2H),2.85-2.81(m,1H),2.38(s,3H),1.75-1.57(m,3H),1.35-1.22(m,3H),1.00(t,3H)。
化合物80:MS:m/z 530.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.24(t,1H),8.70-8.57(m,1H),7.90-7.79(m,2H),7.48-7.36(m,2H),4.05-3.90(m,1H),3.82-3.75(m,1H),3.61(s,3H)3.42-3.39(m,1H),3.29-3.27(m,1H),3.21-3.07(m,2H),2.90-2.83(m,1H),2.43(s,3H),1.75-1.60(m,2H),1.43-1.24(m,2H),1.11-0.93(m,3H)。
化合物81:MS:m/z 613.9(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.50(s,1H),8.61(t,1H),8.15(d,1H),7.61-7.56(m,2H),4.03(d,1H),3.77(s,3H),3.66(d,1H),3.31-3.30(m,1H),3.15-3.03(m,3H),2.83(t,1H),1.41-1.32(m,2H),1.18-1.13(m,2H),1.01(t,3H)。
化合物82:MS:m/z 548.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.30(s,1H),8.56(t,1H),7.61-7.49(m,4H),3.77(s,3H),3.68-3.61(m,1H),3.48-3.23(m,2H),3.17-3.05(m,3H),1.90-1.88(m,2H),1.47-1.35(m,2H),1.19(s,3H),0.83(t,3H)。
化合物83:MS:m/z 530.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.20(s,1H),8.63-8.61(m,1H),7.82-7.75(m,2H),7.45-7.33(m,3H),4.12(d,1H),3.75(s,3H),3.65(d,1H),3.30-3.29(m,1H),3.08-3.05(m,2H),2.98-2.88(m,1H),2.79-2.62(m,1H),1.73-1.70(m,1H),1.47-1.21(m,2H),0.99(t,3H),0.82-0.72(m,3H)。
化合物84:MS:m/z 564.0(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.66(s,1H),8.61(s,1H),7.74(s,1H),7.64-7.57(m,3H),3.99-3.94(m,1H),3.75(s,3H),3.36-3.32(m,2H),3.11-3.07(m,3H),1.73-1.61(m,4H),1.23-1.15(m,3H),1.01(t,3H)。
化合物85:MS:m/z 546.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.28(d,1H),8.57(q,1H),8.21(d,1H),7.62-7.50(m,3H),3.77(s,3H),3.67-3.47(m,1H),3.18-3.03(m,4H),2.97-2.90(m,1H),2.05-1.83(m,2H),1.29-1.20(m,1H),0.98(t,3H),0.92-0.80(m,1H),0.54-0.48(m,1H)。
化合物86:MS:m/z 562.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.28(d,1H),8.61(dd,1H),7.65-7.46(m,4H),4.09-3.62(m,5H),3.45-2.54(m,5H),1.61-1.44(m,2H),0.99(t,3H),0.83-0.71(m,6H)。
化合物87:MS:m/z 598.2(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.64(d,1H),8.68-8.61(m,1H),7.81(d,1H),7.63-7.58(m,3H),3.75(s,3H),3.70-3.67(m,1H),3.48-3.36(m,2H),3.19-3.03(m,4H),1.64-1.53(m,2H),1.01(t,3H),0.86-0.84(m,1H),0.52-0.43(m,3H)。
化合物88:MS:m/z 560.2(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.33(s,1H),8.44(t,1H),7.88(d,1H),7.63-7.53(m,2H),7.50(d,1H),4.12(s,1H),3.77(s,3H),3.45-3.42(m,1H),3.19-3.02(m,3H),2.09(s,1H),1.84-1.75(m,1H),1.39-1.32(m,1H),1.28-1.14(m,2H),1.01(t,3H),0.76-0.68(m,1H),0.51-0.38(m,2H)。
化合物89:MS:m/z 566.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.42(s,1H),8.63(t,1H),7.99(d,1H),7.83-7.75(m,1H),7.51(d,1H),7.44-7.39(m,2H),6.36(t,1H),4.80-4.71(m,2H),4.02(d,1H),3.65(d,1H),3.14-3.00(m,4H),2.87-2.80(m,1H),1.75-1.72(m,2H),1.40-1.30(m,2H),1.01(t,3H)。
化合物90:MS:m/z 562.0(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.62(s,1H),8.62(t,1H),8.05(s,1H),7.56-7.47(m,2H),7.17-7.13(m,1H),6.91(dd,1H),6.80(d,1H),4.01(d,1H),3.16-3.04(m,4H),2.87-2.79(m,1H),1.78-1.72(m,3H),1.43-1.25(m,3H),1.00(t,3H)。
化合物91:MS:m/z 566.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.32(d,1H),8.81-8.74(m,1H),8.36(d,1H),7.84-7.76(m,1H),7.53-7.50(m,1H),7.43-7.38(m,2H),4.35-4.11(m,4H),3.80-3.62(m,2H),3.15-2.93(m,3H),1.77-1.63(m,2H),1.28(t,3H),1.00(t,3H)。
化合物92:MS:m/z 580.1(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.21(s,1H),9.54(t,1H),8.33-8.32(m,1H),7.81-7.75(m,1H),7.44-7.33(m,3H),4.84-4.73(m,1H),4.68-4.74(m,2H),4.45-4.41(m,3H),4.38-3.60(m,5H),3.39-2.94(m,2H),1.77-1.50(m,2H)。
化合物93:MS:m/z 612.2(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.64(s,1H),8.97(d,1H),8.27(d,1H),7.62-7.57(m,3H),4.12(d,1H),3.83(s,1H),3.74(s,3H),3.66(d,1H),1.83-1.46(m,3H),1.25(s,3H),0.82(d,1H),0.61(s,2H),0.55-0.52(m,2H)。
化合物94:MS:m/z 552.0(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.28(d,1H),8.34-8.76(m,1H),8.39(d,1H),7.85-7.78(m,1H),7.48-7.40(m,3H),4.37-4.23(m,1H),4.17-4.13(d,1H),3.91-3.60(m,4H),3.30-3.23(m,1H),3.16-3.12(m,2H),3.10-2.99(m,1H),1.80-1.68(m,2H),1.03(t,3H)。
化合物95:MS:m/z 586.2(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.67(s,1H),8.84-8.77(m,1H),8.31(d,1H),7.64-7.59(m,3H),4.40-4.33(m,1H),4.17-4.13(d,1H),3.90-3.64(m,4H),3.27-3.24(m,1H),3.14-3.08(m,2H),3.07-2.96(m,1H),1.80-1.58(m,2H),1.03(t,3H)。
化合物96:MS:m/z 534.2(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.24(s,1H),8.65(d,1H),8.16(d,1H),7.83-7.75(m,1H),7.47-7.35(m,3H),4.81-4.42(m,1H),4.22(d,1H),3.78(s,3H),3.58-3.44(m,1H),3.15-3.06(m,2H),2.82-2.72(m,1H),1.74-1.59(m,2H),1.34(s,2H),1.03(t,3H)。
化合物97:MS:m/z 562.3(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.33(s,1H),8.54-8.50(m,1H),7.93(d,1H),7.62-7.56(m,2H),7.49(d,1H),3.90-3.85(m,1H),3.77(s,3H),3.62-3.56(m,1H),3.40(s,1H),3.28-3.22(m,2H),1.85(d,1H),1.52(d,2H),1.2(s,1H),1.05-1.00(m,6H),0.73(t,3H)。
化合物98:MS:m/z 584.2(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.35(s,1H),8.81-8.75(m,1H),8.39(s,1H),7.61-7.56(m,2H),7.48(d,1H),4.42-4.09(m,2H),3.87(s,1H),3.77(s,3H),3.30-3.25(m,2H),3.06-2.97(m,2H),1.78-1.74(m,2H),1.44-1.37(m,2H),0.80(t,3H)。
化合物99:MS:m/z 544.2(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.24(d,1H),8.65(dd,1H),7.82(dd,1H),7.66(d,1H),7.48-7.42(m,3H),4.10(d,1H),3.79(s,3H),3.66(d,1H),3.18-2.91(m,4H),2.80-2.73(m,1H),1.58-1.43(m,2H),1.02(t,3H),0.86-0.66(m,6H)。
化合物100:MS:m/z 518.2(M+1);1H NMR(300MHz,DMSO-d6)δppm 10.34(s,1H),8.53(d,1H),7.90(s,1H),7.60-7.51(m,3H),4.01(d,1H),3.92-3.86(m,1H),3.76(s,3H),3.70(d,1H),3.56-3.50(m,1H),2.59(d,3H),2.30(t,1H),1.88-1.81(m,1H),1.78-1.74(m,1H)。
实施例2:实时PCR测定(Real-time PCR Assay)
接种HepAD38细胞,并在96孔板上培养,2天后,向细胞中加入含测试化合物但不含四环素的的培养基继续进行培养。化合物处理5天后,收集培养上清液,然后使用LabTurboDNA mini试剂盒提取细胞外DNA,并通过实时PCR进行定量。
使用ABI QuantStudio 3***,以96孔光学平板进行实时PCR测定。将包含正向引子(5'-ACATCAGGATTCCTAGGACC-3')(SEQ ID NO.1),反向引子(5'-GGTGAGTGATTGGAGGTTG-3')(SEQ ID NO.2)和Luna Universal qPCR Master Mix的PCR混合物(体积为24μl)溶液在95℃下培养10分钟,然后进行45次在95℃培养10秒接着在60℃培养10秒的循环之后,使用GraphPad Prism 5进行回归分析以计算50%有效浓度(EC50)值。
使用实时PCR测定法来测试化合物1至100。观察到83个测试化合物(即化合物1-2、4-10、12-13、15-41、43-45、48-49、51-52、54-59、64、68-78、80-81和83-100)的EC50值低于0.1μM;10个测试化合物(即化合物3、11、14、42、46-47、50、63、66和82)的EC50值为0.1至0.3μM;以及7个测试化合物(即化合物53、60-62、65、67和79)的EC50值为0.3至1μM。
其他实施例
说明书中所揭示的所有特征可以以任意的组合方式结合。说明书中所揭示的各种特征可以被起到相同、等同或类似目的的特征所替换。因此,除非另有说明,所揭示的各种特征仅仅是一系列等同或类似特征的示例。
通过以上说明,本领域技术人员可以很容易地确定本发明的主要特征,同时可以在不背离本发明的精神和范围的前提下,对本发明进行各种改变和改良,以使其适用于各种应用和条件。因此,其他的实施方式也在所附申请专利范围之内。
序列表
<110> 太景生物科技股份有限公司(TaiGen Biotechnology Co., Ltd.)
陈治明(CHEN, Chih-Ming)
<120> B型肝炎抗病毒剂
<130> 80075
<150> US 62/895,626
<151> 2019-09-04
<160> 2
<170> PatentIn version 3.5
<210> 1
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> 正向引物
<400> 1
acatcaggat tcctaggacc 20
<210> 2
<211> 19
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> 反向引物
<400> 2
ggtgagtgat tggaggttg 19
Claims (11)
1.一种式(I)化合物、其药学上可接受的盐、立体异构体、溶剂合物或前药,
其中,
Ra、Rb、Rc和Rd中的每一个独立地是氢、卤素、CN、OH、C1-6烷基、C2-6烯基或C1-6烷氧基,其中,C1-6烷基、C2-6烯基或C1-6烷氧基可各自任选地被1至4个卤素、OH或CN所取代;
X1和X2中的每一个独立地是C或N;
R1和R2中的每一个独立地是氢、CN、OH、卤素、C1-6烷基、C1-6烷氧基、C2-6烯基、C3-12碳环基、C3-12杂环基、芳基或C5-14杂芳基,其中,C1-6烷基、C1-6烷氧基、C2-6烯基、C3-12碳环基、C3-12杂环基、芳基或C5-14杂芳基可各自任选地被1至4个氘、卤素、OH、CN、C1-6烷基、C1-6烷氧基或C3-12碳环基所取代;
R3是氢、卤素或可任选地被1至4个氘或卤素所取代的C1-6烷基;
或是R1和R3可与其邻接的原子一起形成C3-12碳环基、C3-12杂环基或C5-14杂芳基,其中,C3-12碳环基、C3-12杂环基或C5-14杂芳基可各自任选地被1至4个卤素、OH、CN、NH2、C1-6烷基、C2-6烯基、C1-6烷氧基、C3-12碳环基、C3-12杂环基、芳基或C5-14杂芳基所取代;
W不存在或可为NR5;
R5为氢、可任选地被1至4个卤素所取代的C1-6烷基;
Z是C3-12杂环基、C3-12碳环基、C1-6烷基(C3-12碳环基)或C1-6烷基(C3-12杂环基),其中,C3-12杂环基、C3-12碳环基、C1-6烷基(C3-12碳环基)或C1-6烷基(C3-12杂环基)可各自任选地被1至4个卤素、CN、可任选地被1至4个卤素所取代的C1-6烷基或是可任选地被1至4个卤素所取代的C1-6烷氧基所取代;
L是-S(O)2-、-NHS(O)2-、-S(O)2NH-、-NHS(O)2NH-、-S(O)2N(CH3)-、-NHS(O)2N(CH3)-、-(C=O)2-、-NH(C=O)-、-NH(C=O)NH-、-NH(C=O)2-、-(C=O)2NH-、-NH(C=O)2NH-、-(C=O)2N(CH3)-或-NH(C=O)2N(CH3)-;
R4是氢、C1-6烷基、C2-6烯基、C2-6炔基、C1-6烷氧基、C3-12碳环基、C3-12杂环基、芳基或C5-14杂芳基,其中,C1-6烷基、C2-6烯基、C2-6炔基、C1-6烷氧基、C3-12碳环基、C3-12杂环基、芳基或C5-14杂芳基可各自任选地被1至4个卤素、OH、CN、羧基、C1-6烷基、C1-6烷氧基、C3-12碳环基、C3-12杂环基、芳基或C5-14杂芳基所取代;
式中环内的虚线表示单键或双键;
此外,条件是当L为-S(O)2-时,R4不是C1-6烷基。
2.如权利要求1所述的化合物、其药学上可接受的盐、立体异构体、溶剂合物或前药,其中,X1是N,而且X2是C。
3.如权利要求1或2所述的化合物、其药学上可接受的盐、立体异构体、溶剂合物或前药,其中,L是-S(O)2-、-S(O)2NH-、-NHS(O)2NH-、-S(O)2N(CH3)-、-(C=O)2NH-或-NH(C=O)2NH-。
4.如权利要求1至3中任一项所述的化合物、其药学上可接受的盐、立体异构体、溶剂合物或前药,其中,
Ra、Rb、Rc和Rd中的每一个独立地是氢、卤素、CN或可任选地被1至4个卤素所取代的C1-6烷基;
R1和R2中的每一个独立地是氢、CN、卤素、C1-6烷基、C2-6烯基或C3-12碳环基,其中,C1-6烷基、C2-6烯基或C3-12碳环基可各自任选地被1至4个卤素、CN或C3-12碳环基所取代;
R3是氢、卤素或可任选地被1至4个卤素所取代的C1-6烷基;
或是R1和R3可与其邻接的原子一起形成可任选地被1至4个卤素、CN或C1-6烷基所取代的C3-12杂环基;
R5是氢;
Z是C3-12杂环基或C3-12碳环基,其中,该C3-12杂环基或C3-12碳环基可各自任选地被1至4个卤素、CN或是可任选地被1至4个卤素所取代的C1-6烷基所取代;
R4是氢、C1-6烷基、C2-6烯基、C1-6烷氧基、C3-12碳环基、C3-12杂环基、芳基或C5-14杂芳基,其中,C1-6烷基、C2-6烯基、C1-6烷氧基、C3-12碳环基、C3-12杂环基、芳基或C5-14杂芳基可各自任选地被1至4个卤素、OH、CN、羧基、C1-6烷基、C1-6烷氧基或芳基所取代。
5.如权利要求1至4中任一项所述的化合物、其药学上可接受的盐、立体异构体、溶剂合物或前药,其中,
Ra、Rb、Rc和Rd中的每一个独立地是氢、卤素、CN或可任选地被1至4个氟所取代的C1-6烷基;
R1和R2中的每一个独立地是氢、卤素、C1-6烷基、C2-6烯基或C3-6碳环基,其中,C1-6烷基、C2-6烯基或C3-12碳环基可各自任选地被1至4个卤素或C3-12碳环基所取代;
R3是氢、卤素或可任选地被1至4个氟所取代的C1-6烷基;
或是R1和R3可与其邻接的原子一起形成可任选地被1至4个卤素、CN或C1-6烷基所取代的C5-6杂环基;
R5是氢;
Z是含有1或2个氮原子的C3-12杂环基,或是C3-12碳环基,其中,该C3-12杂环基或C3-12碳环基可各自任选地被1至4个卤素、CN或可任选地被1至4个卤素所取代的C1-6烷基所取代;
R4是氢、C1-6烷基、C2-6烯基、C1-6烷氧基、C3-12碳环基、C3-12杂环基或芳基,其中,C1-6烷基、C2-6烯基、C1-6烷氧基、C3-12碳环基、C3-12杂环基或芳基可各自任选地被1至4个卤素、CN、羧基、C1-6烷基、C1-6烷氧基或芳基所取代。
6.如权利要求1至5中任一项所述的化合物、其药学上可接受的盐、立体异构体、溶剂合物或前药,其中,Z是含有1或2个氮原子的C4-8杂环基,该C4-8杂环基可任选地被1至4个卤素或可任选地被1至4个卤素所取代的C1-6烷基所取代。
7.如权利要求1至6中任一项所述的化合物、其药学上可接受的盐、立体异构体、溶剂合物或前药,其中,Z是含有1或2个氮原子的C4-8杂环基,该C4-8杂环基可任选地被1至4个卤素或可任选地被1至4个卤素所取代的C1-6烷基所取代,而且该C4-8杂环基上的氮原子会与L连接。
9.一种药物组合物,其包含权利要求1至8中任一项所述的化合物,以及一种或多种药学上可接受的载体。
10.如权利要求9所述的药物组合物,其可进一步包含一种或多种另外的治疗剂。
11.如权利要求1至8中任一项所述的化合物或权利要求9至10所述的药物组合物用于治疗、预防、或改善有需要的受试者中的HBV感染。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962895626P | 2019-09-04 | 2019-09-04 | |
US62/895,626 | 2019-09-04 | ||
PCT/US2020/049312 WO2021046286A1 (en) | 2019-09-04 | 2020-09-04 | Hepatitis b antiviral agents |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114599636A true CN114599636A (zh) | 2022-06-07 |
Family
ID=74852230
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202080055673.0A Pending CN114599636A (zh) | 2019-09-04 | 2020-09-04 | B型肝炎抗病毒剂 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230012560A1 (zh) |
EP (1) | EP4028394A4 (zh) |
JP (1) | JP2022547088A (zh) |
CN (1) | CN114599636A (zh) |
CA (1) | CA3153358A1 (zh) |
TW (1) | TW202110822A (zh) |
WO (1) | WO2021046286A1 (zh) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150266890A1 (en) * | 2012-08-28 | 2015-09-24 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
CN105452220A (zh) * | 2013-05-17 | 2016-03-30 | 爱尔兰詹森科学公司 | 氨磺酰基吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途 |
US20160115149A1 (en) * | 2013-05-17 | 2016-04-28 | Janssen Sciences Ireland Uc | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
US20170217974A1 (en) * | 2016-02-02 | 2017-08-03 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
US20170240548A1 (en) * | 2016-02-19 | 2017-08-24 | Novartis Ag | Tetracyclic pyridone compounds as antivirals |
US20170253609A1 (en) * | 2016-03-07 | 2017-09-07 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
WO2019017814A1 (ru) * | 2017-07-18 | 2019-01-24 | Александр Васильевич ИВАЩЕНКО | Ингибитор вируса гепатита в (вгв) |
US20190060258A1 (en) * | 2017-08-28 | 2019-02-28 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
CN109843296A (zh) * | 2016-06-10 | 2019-06-04 | 英安塔制药有限公司 | 乙型肝炎抗病毒药剂 |
-
2020
- 2020-09-04 TW TW109130378A patent/TW202110822A/zh unknown
- 2020-09-04 CA CA3153358A patent/CA3153358A1/en active Pending
- 2020-09-04 JP JP2022514736A patent/JP2022547088A/ja not_active Withdrawn
- 2020-09-04 US US17/753,515 patent/US20230012560A1/en active Pending
- 2020-09-04 EP EP20861912.2A patent/EP4028394A4/en active Pending
- 2020-09-04 WO PCT/US2020/049312 patent/WO2021046286A1/en unknown
- 2020-09-04 CN CN202080055673.0A patent/CN114599636A/zh active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150266890A1 (en) * | 2012-08-28 | 2015-09-24 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
CN105452220A (zh) * | 2013-05-17 | 2016-03-30 | 爱尔兰詹森科学公司 | 氨磺酰基吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途 |
US20160115149A1 (en) * | 2013-05-17 | 2016-04-28 | Janssen Sciences Ireland Uc | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
US20170217974A1 (en) * | 2016-02-02 | 2017-08-03 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
US20170240548A1 (en) * | 2016-02-19 | 2017-08-24 | Novartis Ag | Tetracyclic pyridone compounds as antivirals |
US20170253609A1 (en) * | 2016-03-07 | 2017-09-07 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
CN109843296A (zh) * | 2016-06-10 | 2019-06-04 | 英安塔制药有限公司 | 乙型肝炎抗病毒药剂 |
WO2019017814A1 (ru) * | 2017-07-18 | 2019-01-24 | Александр Васильевич ИВАЩЕНКО | Ингибитор вируса гепатита в (вгв) |
US20190060258A1 (en) * | 2017-08-28 | 2019-02-28 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
Non-Patent Citations (1)
Title |
---|
崔美兰;周海洋;刘杰;徐文方;: "抗乙肝病毒化学药物研究进展", 国际药学研究杂志, no. 04, 30 August 2012 (2012-08-30), pages 280 - 285 * |
Also Published As
Publication number | Publication date |
---|---|
CA3153358A1 (en) | 2021-03-11 |
JP2022547088A (ja) | 2022-11-10 |
US20230012560A1 (en) | 2023-01-19 |
EP4028394A1 (en) | 2022-07-20 |
EP4028394A4 (en) | 2023-10-11 |
WO2021046286A1 (en) | 2021-03-11 |
TW202110822A (zh) | 2021-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI809395B (zh) | Gpr6的四氫吡啶並吡調節劑 | |
CA2756568C (en) | Kinase inhibitors and method of treating cancer with same | |
US9884844B2 (en) | Heterocyclic compounds and methods of use thereof | |
DK2800748T3 (en) | CYCLIC AMIDE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE AND APPLICATIONS THEREOF | |
AU2016229101B2 (en) | Glucosylceramide synthase inhibitors for the treatment of diseases | |
JP2024505735A (ja) | 置換されたピリダジンフェノール系誘導体 | |
JP6110474B2 (ja) | Ccr2の縮合シクロペンチル拮抗薬 | |
CN111065639B (zh) | 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途 | |
TW201040180A (en) | Cyclic compound having a substituted phenyl group | |
KR20190077312A (ko) | 디하이드로피리미딘 화합물 및 이러한 화합물의 제조 방법 및 용도 | |
CN115413279A (zh) | P2x3调节剂 | |
AU2012367780A1 (en) | Derivatives of aza adamantane and uses thereof | |
MX2010014501A (es) | Antagonistas de piperidil acrilamida de receptor 2 de citocina quimioatrayente. | |
CN114599636A (zh) | B型肝炎抗病毒剂 | |
US20220098169A1 (en) | Antiviral agents | |
CN114901649A (zh) | Ssao抑制剂及其用途 | |
CN115536699B (zh) | 一种新型EGFR-TKIs、制备方法、药物组合物及其应用 | |
CN114790164B (zh) | 一种取代的异吲哚啉-1,3-二酮类pde4抑制剂及其药物用途 | |
AU2020369579A1 (en) | Quinolone carboxylic derivatives | |
JP2023549962A (ja) | Pu.1阻害剤としての化合物 | |
US20210322362A1 (en) | Antiviral 1,3-di-oxo-indene compounds | |
TW202333713A (zh) | 一種噠嗪類化合物、其藥物組合物及應用 | |
CN113683613A (zh) | 一种多环吡啶肟基化合物及其药物组合物和用途 | |
CN112076180A (zh) | 抗高血压的多元醇化合物及其衍生物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |